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1.1 ABSTRACT 
Recently the dynamic association between the immune system and the skeletal 
system has become appreciated. However, to date there has been no attempt at 
manipulating CD4+ and CD8+ T lymphocytes during fracture repair. This study was 
aimed at evaluating whether patients and animals with a perturbed lymphocyte 
function have an abnormal bone fracture repair. 
The in vivo study involved the creation of a standard closed tibia fracture in BALB -c 
mice depleted in CD4+ or CD8+ T lymphocytes compared to wild type controls. 
Bone fracture repair was investigated using radiographs, biomechanical testing, 
stereology and immunohistochemistry. The CD4+ depleted group had significantly 
greater callus size at days 7 and 14 compared to controls (p <0.001). Stereology 
confirmed a significantly greater proportion of bone than cartilage compared to the 
CD8+ depleted group. The CD8+ depleted group had a significantly greater callus 
size at days 7 and 21 post fracture compared to controls (p <0.005). However 
stereology demonstrated that the fracture callus had significantly more cartilage and 
less bone compare to CD4+ depleted, indicating the callus was less mature.. This in 
vivo study has revealed the positive role of CD8+ T lymphocytes on fracture repair 
and suggested a potential inhibitory role of CD4+ T lymphocytes. 
Overall this study has suggested that a perturbed lymphocyte function in animals 
affects fracture repair. 
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Over 2 million fractures occur per year in the UK 1,2. Fractures may be the result of 
high energy or low energy trauma, such as a fall from a standing height. High energy 
fractures are often associated with multiple injuries which require a variety of 
surgical specialities and resources. The breath of specialities is often absent from the 
average district general hospital leading to inconsistent and variable quality of 
treatment 3. Mortality remains high in these trauma patients. Yet if they do survive, 
many do so with disability that creates high socioeconomic burden4. Regional trauma 
centres dedicated to providing specialist 24 hour care have been shown to reduce this 
mortality 5. As a consequence trauma services in England are currently being 
reorganised into regional trauma centres 6. Estimates suggest this concentrated 
reorganisation of services could save an additional 450- 600 lives 6 . 
In contrast low energy fractures are common. Hip fractures are one type of low 
energy fracture which account for over 6,000 fractures per year in Scotland7. Of 
those 90% are in people aged over 55 years and 80% are female with osteoporosis 8. 
Currently the cost to NHS Scotland of treating osteoporotic hip fractures is £73 
million per annum 8. With the Scottish population predicted to climb above 5 million 
by 2050 and the elderly population set to rise, fragility fractures such as hip fractures 
will be an increasing problem 9,1O The consequences of hip fractures are devastating. 
Many patients loose full mobility with the added consequence of loss of 
independence, and the inability to live alone in their own home. The Scottish Hip 
Fracture Audit reported that only 53% of patients who had lived independently, 
without carers, returned to this level of independence 120 days after fracture 7. 
Combining this loss of independence with ongoing pain and confusion only 
compounds the burden of illness. 80% of elderly patients have reported that they 
would rather die than suffer the consequences of a hip fracture 11. The mortality rate 
after hip fracture remains high. The reported rates in the UK are of 23% at 6 months 
and 28 -30% at one year 7,12. These exceed the combined annual death rate from 
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ovarian, uterine and breast cancer 13. Accordingly the importance of bone fracture 
repair will become more apparent not only to the Scottish NHS but to the UK NHS 
and world healthcare7. 
The emerging field of 'Osteoimmunology' is changing our understanding of bone 
physiology and regeneration, and it will likely play an important role in the design of 
future clinical intervention strategies. Fracture repair is a wound healing process that 
in young healthy patients usually proceeds to uncomplicated union. However, the 
healing cascade is delayed with increasing age 14, smoking 15, medication 16 and 
certain diseases such as osteoporosis. This has consequences on the patient's 
management and the economic costs to the healthcare provider. Frequently the older 
aged patients who sustain fractures are also prescribed a range of medications, many 
of which are know to alter the immune system. For example, non -steroidal anti - 
inflammatory drugs (NSAIDs) and steroids such as prednisolone, alter the immune 
cells function through a range of important molecules such as prostaglandins 17,18. In 
addition to their anti -inflammatory activity, this category of drugs are also associated 
with a reduced ability to repair bones, which points to the importance of the immune 
system in the fracture repair process 19. Besides the known effects of anti - 
inflammatory molecules, little research has been undertaken to determine the role of 
components of the immune system in the fracture repair process. A knowledge of 
these mechanisms would contribute to the development of improved bone repair. 
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3.0 CURRENT CONCEPTS 
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3.1 FRACTURE REPAIR 
Fracture repair is a wound healing process which involves a dynamic interaction 
between cellular mediators and signalling molecules. There have been 2 types of 
repair described, primary and secondary bone healing 20,21 
3.1.1 PRIMARY BONE HEALING 
Primary bone healing involves the direct attempt of the bone to reestablish the 
haversian bone system without the formation of a callus. Certain conditions need to 
be established to achieved this. Firstly, the fracture has be to anatomically reduced, 
with the direct anatomical contact of both bone cortices of less than 100µm 22 
Secondly, movement at the fracture site has to be less than 1% strain, so if strain is 
100µm then movement is 1µm 22. This is achieved by rigid internal fixation. Under 




Figure 1: Low power photomicrograph of a cutting cone. (Stain: hematoxylin and eosin, 
magnification x25) Reproduced from Einhorn, T (1988) The cell and molecular biology of 
fracture healing, Clinical Orthopaedics and Related Research 355S,pp. S7 -S21. 
These are channels, parallel to the longitudinal axis of the bone which are formed by 
multicellular osteoclasts 23. These channels allow revascularisation and the 
introduction of undifferentiated mesenchymal cells with the capacity to differentiate 
into osteoblasts 21. Once formed the osteoblasts circumferentially lay down new 
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osteoid at a rate of 1 µm per day24 . Primary bone healing has the advantage of 
immediate fracture stability over secondary healing due to artificial absolute stability, 
although the time to fracture union is slower. 
3.1.2 SECONDARY BONE HEALING 
The majority of fractures heal by secondary bone healing 21. It involves a 
combination of endochondral and intramembranous ossification using callus 
formation. Endochondral ossification is the process of bone formation where 
cartilage acts as an osteoconductive strut for osteogenic stem cells to lay down new 
bone matrix25. The cartilage intermediate acts not as a biological but a physical 
scaffold. It is characterised by the formation of type X collagen Z6. Conversely 
intramembranous ossification forms bone directly from differentiated mesenchymal 
cells without a cartilage intermediate. In contrast to primary bone healing secondary 
bone healing is limited by rigid fixation and enhanced by a degree of motion 27. 
Secondary bone healing is a continuous process, from initial fracture to bone 
remodelling. Yet it is frequently considered as 4 discrete phases: 1) Haematoma 2) 
Inflammation 3) Repair 4) Bone remodelling 27. The initial trauma causes damage 
to the surrounding muscles, periosteum, bone marrow and blood vessels leading to 
bleeding and the formation of a primary platelet haematoma, figure 2. This occurs 
shortly after injury. Cells within and around the haematoma, particular platelets and 
inflammatory cells, release growth factors, including Transforming Growth Factor ß 
(TGF1), Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth 
Factor (VEGF)28 and cytokines, Tumour Necrosis Factor alpha (TNF a) and 
Interleukin 1(IL -1) 21,29. These growth factors and cytokines then stimulate the 
migration of macrophages and fibroblasts, as well as the formation of chondroblasts 
and osteoblasts 29. This is start of the inflammatory phase where initially the 
haematoma is removed by phagocytosis and replaced by the formation of a thin, 
fibrin like mesh, interwoven with blood vessels known as soft granulation tissue 20. 
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This soft granulation tissue bridges the fracture gap. Simultaneously, at the cambium 
layer of the periosteum a woven or hard callus bridge starts to form, figure 2 30 
Secondary fracture healing: bridging of a fracture by external callus 
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Figure 2: The phases of fracture repair reproduced from Westerman RW, Scammel BT 
Principles of bone and joint injuries and their healing. Science 2012;30(2): 54 -60 30 
The repair phase then proceeds through the formation of hard callus at the 
periosteum to create a bridge, spanning the fracture site figure 2. As a result the 
fracture gains stability with a reduction in strain (original length over a change in 
length). Mature osteoblasts are particularly sensitive to strain and cannot tolerate 
strains of >1% 3 i . With a reduction in strain osteoblasts can now invade the soft 
granulation tissue. 
The soft granulation tissue is firstly replaced with cartilage then woven bone by the 
process of endochondral ossification, figure 2 24. The new matrix formed is then 
mineralised by the action of osteoblasts and chondrocytes 20. Vascularised channels 
then penetrate the mineralised matrix. 
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The final bone remodelling phase then continues long after the fracture has clinically 
united. Osteoblasts replace the disorganised woven bone by organised lamellar bone 
and the central haversian canal system is reestablished by osteoclasts, figure 2,24. 
Eventually through this process of remodelling the original bone structure and 
strength is reinstated to the fracture callus. 
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3.2 FRACTURE INHIBITION AND NON UNION 
Fracture repair is a complex process which can be impaired, leading to delayed union 
or inhibited, causing non union. Non union involves cessation of both the periosteal 
and endosteal healing processes such the fracture is not bridged 32. The factors which 
lead to fracture non union involve both the biology of the fracture i.e. the patient, and 
the mechanics around the fracture. These will be subsequently described. 
3.2.1 PATIENT FACTORS 
3.2.1.1 AGE 
Children heal fractures much quicker than adults. The immature skeleton is actively 
growing, providing the environment for rapid osteogenic cell production when a 
fracture occurs. Combining this with a stronger, thicker periosteum and a larger 
subperiosteal haematoma allows for a rapid production of callus which stabilises the 
fracture earlier 33. 
Evidence suggests in adults, increasing age leads to impairment of healing 34 and 
increased prediction of non union 14. In vivo studies of fracture healing in elderly rats 
have indicated a reduction in cartilage and bone formation 35. Further studies by Lu 
et al compared fracture healing in juvenile (4 weeks), middle aged (6 months) and 
elderly mice (18 months) from day 3 to 35 post fracture 36. Overall they found a 
reduction in fracture repair rates in the elderly mice compared to juvenile mice, with 
a smaller callus size, a delay in vascularisation of the callus and less overall bone 
quantity on histomorphology 36. 
3.2.1.2 GENDER 
There has been little evidence linking gender to fracture non union. Although 
complications of healing are more common in males this is frequently due to the 
increased rate of high energy fractures 16. 
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3.2.1.3 SMOKING 
Increasing evidence has indicated the deleterious effect of smoking on fracture 
healing 16,37,16 Castillo et al 38 prospective multicentred trial of 268 open tibial 
fractures (n =105 current smokers, n= 82 previous smoker and n= 81 non smokers) 
showed current smokers had a 37% risk of non union whilst previous smokers had a 
32% risk. Interestingly the risk of further complications including infection and 
osteomyelitis were significantly increased in both these groups 38. The exact 
pathology of how smoking inhibits fracture healing remains unclear although several 
hypothesis have been suggested; a reduction in blood supply, a reduction in oxygen 
tension, an increase in reactive oxygen intermediates and lower concentrations of 
anti -oxidants vitamins 16'39. Gullihorn L et al 40 have further suggested that it is the 
smoke, rather than the nicotine which reduces the activity of osteoblasts. 
3.2.1.4 DIABETES MELLITUS 
The effect of diabetes on fracture repair has been well described in experimental 
studies with an overall reduction in tensile- strength of the fracture callus and delayed 
fracture union 41. One study by Diniz et al 42 used Alloxan, a chemical agent to 
selectively destroy pancreatic B islet cells in 24 BB Wistar rats causing diabetes. At 
day 7 post fracture they identified a reduction in cartilage formation and increase in 
connective tissue at the fracture site in the diabetic rats compared to controls. Beam 
et al 43 used biogenetical bred BB Wistar rats as a fracture model for autoimmune 
diabetes, a similar homolog to type 1 diabetes in humans. This well conducted study 
identified similar results with reduced cellular proliferation, reduced osteoblast 
activity, and reduced synthesis and content of collagen compared to controls. 
However they noticed that these defects in fracture healing could be restored, nearly 
to normal, when the glucose level was tightly controlled 43. 
Clinical studies have also highlighted the negative effects of diabetes on fracture 
repair. Loder 44 reported that the rate of fracture repair was delayed by 87% in 
diabetic patients compared to controls. A retrospective study by Kline et al 45 
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investigated the rates of early complications after operative fixation of pilon ankle 
fractures in diabetic patients compared to non diabetic controls. They identified the 
non union rate in the diabetic group to be 43% compared to 16% in the non diabetic 
group 45 
From a cellular level, studies have shown the impaired cellularity and reduced 
cartilage production in diabetic could be accounted for by a reduction in levels of 
undifferentiated Mesenchymal Stem cells (MSC) and recruitment of the osteoblastic 
lineage46. It also has been postulated that a reduction in growth factors, particularly 
platelet- derived growth factors could also lead to reduced cell proliferation 47. 
Gandhi et al 48 study demonstrated this by local delivery of platelet rich plasma 
(PRP), a concentration of growth factors, to BB Wistar diabetic rats (n =24). They 
then compared fracture healing in this group to controls (n =23) and diabetic rats 
devoid of plasma rich plasma (n =22). They observed the restoration of normal cell 
proliferation and chondrogenesis at the early stages of fracture repair in the locally 
delivered PRP group 48. The mechanical strength of the fracture callus in the diabetic 
PRP group had also significant improved compared to the diabetic group (p <0.01) 
but not to the control group 48. 
3.2.1.5 MEDICATION 
Medications can inhibit the fracture repair process. Non steroidal anti -inflammatory 
drugs (NSAIDS) are one such example which inhibit cyclooxygenase (COX) activity 
and prevent production of prostaglandins. Although conflicting evidence exists, the 
majority have shown NSAIDS effect the inflammatory phase of fracture repair 
leading to delayed union 31. In vivo studies by Altman et al 49 showed a significant 
reduction in mechanical strength, and delay in maturation of the fracture callus in 
rats given ibuprofen or indomethacin post fracture compared to controls. Further 
studies by Beck 5° and Murnaghan et al 51 confirmed their inhibitory effect. 
Murnaghan et al 51 study used rofecoxib, a selective COX 2 inhibitor, in a mouse 
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model and identified that the NSAIDS negative effect on fracture repair was 
independent of their inhibition of angiogenesis. 
These fmdings have been supported by a small study of 32 patients with femoral 
diaphyseal fractures, who demonstrated a strong association between NSAIDS and 
fracture non union 52. In addition, Burd et al 53 provided additional evidence for an 
inhibitory role of NSAIDs. They carried out a large prospective randomized control 
study using indomethacin in patients with acetabular fractures with associated 
concomitant fractures. Of those patients who received indomethacin 29% had an 
associated long bone non union compared to 7% in the control group (p= 0.004) 53 
Glucocortiosteroids are frequently prescribed to Rheumatoid arthritis patients during 
their initial diagnosis or during flare ups of their disease. These steroids act by 
binding to the glucocorticoid receptor on cells, with the effect of reducing 
inflammation and the immune response. Unfortunately their initial benefits are 
complicated by a variety of sides effects when used long term, such as osteoporosis 
and increased risk of fracture. In addition, they have an inhibitory effect on fracture 
repair 16. A study by Waters et al 54 of non critical ulna osteotomies in rabbits given 
subcutaneous prednisolone showed radiographic delay of fracture union. 15% of the 
group receiving prednisolone achieved union at 6 weeks compared to 81% in the 
control group 54. Mechanical testing of the callus confirmed this, with a reduction in 
stiffiiess and torque in the prednisolone group compared to controls 54. However, 
other investigations have highlighted that short term use may not be so detrimental. 
An in vivo study of 3 days of subcutaneous prednisolone post fracture demonstrated 
no negative effects on fracture repair when compared to controls, up to 4 weeks post 
fracture 55 
Disease modifying anti rheumatoid drugs (DMARDs) such as methotrexate, a folate 
reductase inhibitor, are used in rheumatoid patients. Although evidence is limited in 
Rheumatoid arthritis patients, DMARDs have been shown to affect fracture repair in 
32 
children with acute lymphocytic leukaemia 56. A case series by Stanisavljevic and 
Babcock 57 studied the effect of methotrexate on 37 children with acute lymphocytic 
leukaemia. 7 children (19 %) sustained multiple fractures of which 3 children (42 %) 
went on to develop delayed union or non union. Only 2 of these fractures healed after 
removal of the methotrexate, the third had to have surgical intervention with open 
reduction, internal fixation and bone graft to bring about healing. 
In vivo studies by Pelker et al 58 have reinforced the inhibitory effect of methotrexate 
on fracture repair. They observed the biomechanical effects of methotrexate on 
femoral osteotomies in rats for 16 weeks. Using load deformation curves they 
showed an earlier stage of fracture repair in the methotrexate group compared to 
controls at 16 weeks (p <0.01). Torsional stiffness in the methotrexate group was also 
lower than control but this was not significant. Although the study showed an overall 
delay in healing in the methotrexate group no comparison was made of the torque to 
failure between the groups, which may have been significant. 
3.2.2 MECHANICAL PROPERTIES 
The mechanical properties of the fracture have a significant effect on whether a 
fracture will unite or lead onto non union. These will now be described in more 
detail. 
3.2.2.1 ANATOMICAL LOCATION 
The anatomical location of the fracture, particularly which bone is involved effects 
fracture repair. Specific bones are more susceptible to fracture non union than others 
e.g scaphoid, talus, navicular, lunate. The reason for this is commonly due to the 
precarious blood supply to that bone. For example the blood supply to the scaphoid is 
mainly from the radial artery with the proximal pole receiving 70 -80% of its blood 
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supply from vessels entering through the dorsal ridge 59. The tuberosity and 20 -30% 
of the distal pole receive blood from the volar branches of the radial artery and 
superficial palmar branch 59. The importance is that the majority of the dorsal and 
volar vessels that supply the scaphoid enter the distal third of the bone 60. 
Consequently a fracture to the proximal pole disrupts the blood supply to this area, 
leading to a higher incidence of non union 61. 
3.2.2.2 COMMINUTION 
Comminution of fracture is defined by a fracture having more than 3 fracture 
fragments. Frequently comminuted fractures are associated with high energy trauma 
and soft tissue injury 62. Studies have shown comminuted fractures are at increased 
risk of non union 62. Robinson et al 63 prospective epidemiological study on clavicle 
fractures showed a higher risk of delayed union and non union in the severely 
comminuted midshaft clavicle fractures compared to the more simple midshaft 
fracture group (OR = 2.59, 95% CI 1.38 to 4.84). 
3.2.2.3 DISPLACEMENT 
Displacement of fracture, the distance between fracture fragments measured on 
radiograph, is important to fracture healing. Evidence suggests displaced fractures 
frequently take longer to heal, require longer immobilisation and are associated with 
higher rates of non union 6364. The displacement maybe due to the opposition of 
muscles, periosteum or soft tissue interposition 65,66 
The critical level of displacement to delay or inhibit fracture healing varies on the 
location of the fracture. In scaphoid fractures displacement is defined as greater than 
1 mm or more, or angulation of the radioscaphoid angle of >15 degrees or a 
scapholunate angle >60 degrees 60. However in a middle third clavicle fracture 
displacement is defined as greater than 100 %. The amount of displacement and its 
associated non union risk is an indication for surgical fixation. 
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3.2.2.4 FRACTURE TREATMENT 
Most fractures heal without surgical intervention. However there are some fractures 
for which surgical intervention is indicated e.g a volar displaced distal radius fracture 
with carpal malalignment. It is critical at the time of surgery that if primary bone 
healing is to be established the fracture must be well reduced, with rigid fixation and 
no fracture gap 22. Animal studies have shown a fracture gap of >1mm inhibits bone 
healing 67. Therefore it is important that the environment for primary or secondary 
bone healing is achieved by the surgeon. Poor fixation would impair fracture healing 
and lead to non union. 
Secondary bone healing, as previous described in section 3.1.2, requires some 
micromotion at the fracture site to promote healing rather than rigid fixation 27. This 
movement, in the case of tibial fractures, has been shown to be of benefit if applied 
axially 68. However exceeding the magnitude of strain, exposing the fracture to 
excessive interfragmentary shear or rotational movements would also inhibit fracture 
repair 69. Excessive motion would cause the fracture repair to undergo hypertrophic 
non union with formation of a large callus but failure of it to bridge the fracture 
fragments. Such an outcome maybe the result of a defect in fracture stabilisation, 
either by poor surgical technique, or failure of fixation device 16 
3.2.2.5 OPEN FRACTURES 
Open fractures are frequently the result of high energy trauma. Gustilo and Anderson 
originally classified them into 3 types based on wound size, level of contamination 
and fracture comminution 70, table I. However the type III were further subdivided by 
Gustilo et al 71 into ILIA, IIIB and IIIC due to the complexity of the associated 
injuries, table I. Overall the classification system has indicated the association 
between high grade and worse clinical prognosis, particularly infection and non 
union 70. Further studies have shown similar results 72. Caudle and Stern73 showed in 
their study of 63 tibial shaft fractures a non union rate of 27% for type ILIA, rising to 
43% inType IIIB and a 100% complication rate for type IIIC fractures. Of these 
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Wound <1 cm, Fracture simple /minimal 
comminution 
II 
Wound >1 cm moderate soft tissue injury 
Fracture -moderate comminution 
III 
Farmyard injuries, Gun shot wounds 
Diaphyseal segmental bone loss 
Segmental fracture with displacement 
IIIA 
Open fractures with adequate soft tissue 
coverage of a fractured bone despite extensive 
soft tissue laceration or flaps, or high- energy 
trauma irrespective of the size of the wound 
IIIB 
Open fractures with extensive soft tissue injury 
loss with periosteal stripping and bone exposure. 
This usually is associated with massive 
contamination 
IIIC 
Open fractures associated with arterial injury 
requiring repair 
Table I Gustilo- Anderson Classification of Open fractures adapted from Gustilo RB. 
Mendoza RM.Williams DN.Problems in the management of type Ill (severe) open fractures: 
a new classification of type Ill open fractures. J.Trauma1984 24(8):742 -746 71 
3.2.2.6 PATHOLOGICAL FRACTURES 
Pathological fractures occur when the fracture transects abnormal bone which is the 
result of benign, or malignant disease. These patients pose a difficult treatment group 
as often their treatment involves radiotherapy, which inhibits fracture repair 74. 
Reports have cited non union rates in pathological fractures between 68- 94% for a 
variety of cancer types, treated by different surgical modalities 75.74. Harringon et al 
76 reported that pathological fractures secondary to breast cancer had a greater 
propensity for union than other metastatic cancers. Gainor and Buchert 74 prospective 
study reviewed the rates of fracture non union in 129 patients with metastatic 
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malignancy. They found the overall non union rate for the population to be 65% 74. 
At 1 year the specific rates of non union were, renal cell cancer 25 %, breast cancer 
24% and multiple myeloma 18 %. Unfortunately none of the 17 patients with 
metastatic lung cancer survived longer than 6 months for follow up. As a result they 
found that a life expectancy of greater than 6 months was the primary factor in 
determining bone union (75 % of those patients that lived longer than 6 months went 
on to bone union). No internal fixation of the fracture, and receiving a total post 
operative radiation of greater than 3000 rads were both associated with increased 
rates of non union 74. These results, although interesting, must be reviewed within the 
limitations of the paper. The number of patients in each treatment and radiation 
groups varied widely e.g Only 8 patients were in the >3000 rad radiation group 
compared to 45 patients in the <3000 rad radiation group. These differences between 
the groups and the low numbers could of accounted for the results. There was no 
statistical tests to identify if the differences found were significant or due to chance 
alone. Although some of the patients were given chemotherapy as part of their post 
operative treatment this appears to have not been taken into account in the results. 
This is important as chemotherapy has been reported to effect fracture healing 77. 
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3.3 FRACTURE REPAIR AND THE IMMUNE SYSTEM 
Recently investigators have started to explore the complex association between the 
immune system and the skeletal system 78,79. Components of both the innate and 
adaptive immune system have been reported to have a role in modulating bone 
density. 
3.3.1 THE INNATE IMMUNE SYSTEM 
The innate immune system consists of a variety of non specific cells which recognise 
and respond to pathogens, giving the host immediate defence to infection. The 
cellular components of the innate immune system mainly consists of macrophages, 
mast cells, monocytes, natural killer cells and polymorphonuclear leucocytes. These 
cells are capable of lysing tumour and virally infected cells without prior exposure 80. 
Expression of their cytotoxic activity is limited until they are recruited or activated. 
However once activated they express a potent cytotoxic ability. Mast cells when 
activated are able to released a variety of cytokines and proteolytic enzymes, 
particularly chymase. Studies have shown that through the action of chymase mast 
cells are involved in the early stages of fracture repair, modifying the extra cellular 
matrix, and affecting angiogenesis 81. 
Macrophages are phagocytes with the ability to engulf and digest cellular pathogens 
and debris. They are also involved in producing cytokines and have been identified in 
the early phase of fracture repair. In 'vitro studies have shown they are capable of 
producing known osteoinductive signals such as bone morphogenic protein -2 
(BMP -2) 82,83. Further in vivo studies have reinforced the importance of macrophages 
in fracture repair. For instance Kobayashi et al 84 studied fracture repair in mice 
depleted in the macrophage migratory inhibitory factor (MIF) gene. MIF is a 
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cytokine produced mainly by macrophages which regulates their function 85. In their 
study they observed an increase in new bone volume but a reduction in strength and 
mineralisation of the fracture callus in the MIF deficient group compared to controls. 
They attributed this delay in bone mineralisation of the fracture callus to the absence 
of macrophages 84. Recently Alexander et al 86 have supported this theory by 
identifying specific macrophages, osteomacs, which are required for type I collagen 
formation and the mineralisation of the fracture callus. 
Monocytes, like macrophages are a type of white blood cell involved in 
phagocytosis, cytokine production and antigen presentation. They have a role in the 
early inflammatory phase of fracture repair. Clinical work by Tang et al ß7 have 
showed Caveolin 1, a monocyte transmembrane signalling protein, to be both present 
and increased in patients 9 -12 days after bone fracture. 
Besides advancing the fracture repair process certain cells of the innate immune 
system have been shown to be detrimental.Polymorphonuclear leucocytes which 
remove infectious agents by phagocytosis appear from in vivo studies to have a 
inhibitory effect on fracture repair. This concept is supported by the work of Grogaad 
et al 88 who observed the effect of depletion of polymorphic neutrophils within the 
first 72 hours of femoral fracture repair in rats using injections of polymorphonuclear 
leucocyte anti serum. They reported no difference in the amount of bone formation 
on radiological examination. Yet, on mechanical testing a significantly greater 
bending strength was identified in the depleted polymorphic group compared to 
controls 88. The absence of histological outcomes and described analysis of the 
radiographic outcomes of the fractures suggested that this paper may not be a true 
representation of the effect of Polymorphonuclear leucocytes in fracture repair. 
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3.3.2 THE ADAPTIVE IMMUNE SYSTEM 
The adaptive immune system is composed of a group of highly specialised cells, 
mainly T and B lymphocytes, which are stimulated by the innate system to respond 
to invasion of pathogens. Unlike the innate immune system, these cells have the 
ability to develop a memory of previous pathogen exposure so enabling a future 
exposure to have a greater, and more rapid response. 
Immature B lymphocytes are characterised by a surface antigen B -cell receptor 
(BCR) 89. Activation of the B lymphocyte is via a T lymphocyte antigen mediated 
response to the surface BCR. It results in the differentiation of the B lymphocyte into 
either a plasma cell or a memory B cell 89. Plasma cells have the ability to secrete 
antibodies which acts as part of the humoral component of the adaptive immune 
system 90. Memory B cells can respond rapidly to a secondary antigen exposure. 
Besides these roles B lymphocytes are important in coordinating other immune cells, 
particularly T lymphocytes, by antigen presentation or cytokine production89. In vivo 
studies of immune responses in wild type mice depleted in B lymphocytes have 
showed a significant reduction in CD4+ T lymphocyte activity to foreign and self 
antigens 91 
T lymphocytes are characterised by the presence of a surface T cell receptor (TCR) 
and can be divided into 6 subclasses, Helper (CD4 +), Cytotoxic (CD8 +) , Memory, 
Regulatory, Natural killer and gamma delta T cells (ay), all with different roles. 
Helper T lymphocytes (TH) are also known as CD4+ T lymphocytes due to the 
expression of the membrane CD4 protein on their cell surface. They are activated by 
presentation of peptide antigens presented on Major Histocompatibility Complex II 
molecules (MHC II) which are present on the surface of antigen presenting cells 
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(APC). Once activated they can divide into 3 further subtypes TH1, TH2 and TH3 92. 
All these subtypes produce different soluble cytokines, required to facilitate different 
immune responses 92. For example- interferon y( IFN -y) acts as a macrophage 
activating factor, stimulating the macrophage and leading to death of the 
microorganism . 
Cytotoxic T lymphocytes are also known as CD8+ T lymphocytes due to the 
presence of the CD8 glycoprotein on their cell surface. Their role is to destroy 
tumour and viral infected cells. Unlike CD4 T lymphocytes they are activated by 
antigens presented on MHC I molecules. These MHC I molecules are present on 
nearly every cell surface in the body. Once activated they cause apoptosis of the 
infected virus cell by activation of cytotoxic proteases, caspases, within the target 
cell 93. Recently an important role of CD8 T lymphocytes in regulation of CD4+ T 
lymphocytes differentiation has been reported in in vivo studies involving 
experimental T lymphocyte induced autoimmune encephalomyelitis (EAE). Jiang et 
al 94 showed the protection of EAE development when CD8 T lymphocytes were 
present. Depletion of CD8 + T lymphocytes in the same murine group resulted in the 
development of EAE 94 
Memory T cells are a type of antigen specific T lymphocytes which remain for a long 
time after exposure from the original antigen. T memory cells specific for Tetanus - 
toxoid have been detected in the circulation of antigen primer individuals 10 years 
after initial antigenic stimulation 95. There have been 2 subtypes described, Central 
Memory T cells ( TcM) and Effector memory T cells (TEM) which either can be CD4+ 
or CD8+ 96. TcM are CD45RO+ memory cells which constantly express CCR7 and 
CD62L receptors. It is these receptors which allow the TcM to be able to migrate to 
secondary lymphoid organs and pass through high endothelial vessels 96. Once 
activated by antigens they produce interleukin 2 (Il -2) and then readily differentiate 
into effector cells which produce IFNy or interleukin 4 (IL -4) 96. In contrast TEM cells 
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lack the CCR7 receptor but instead express chemoreceptors and adhesion molecules 
allowing them to migrate effectively to sites of inflammation 96. 
Regulatory T cells (Tregs) are another type of T lymphocyte which can be divided into 
2 distinct types, natural or thymic derived Tregs and inducible Tregs 93. Natural Tregs 
are generated in the thymus and have the surface receptors CD4+ and CD25 +. They 
represent approximately 10% of the T lymphocytes in the circulation and can be 
distinguished from induced Tregs by the presence of the intracellular molecular 
FoxP3 97. It appears their role is to maintain self tolerance so preventing autoimmune 
and inflammatory diseases although the exact mechanism is not entirely understood 
93. In contrast induced Treg are produced from native T lymphocytes in the peripheral 
circulation after antigen activation by dendritic cells 93. Induced Tregs are diverse 
and been divided into type 1 regulatory cells (Tri) and T helper type 3 cells (TH 3 ) 
98. Both cells cause suppression, either to the antigen -specific immune response (Trl 
cells) or proliferation of T lymphocytes (TH 3 cells) 98. 
Natural killer T lymphocytes are a type of T lymphocyte which express both the TCR 
receptor and the C- lectin -type receptor NK1.1 93. Their role involves recognition of 
glycoproteins and microbial antigens from mycobacteria. Once activated they secrete 
cytokines such as IFNy and IL4 93. They also produce cytotoxic granules which are 
directly delivered to the target cell synapse leading to eventual apoptosis of the target 
cell 93 
Gamma delta T cells (y /S) are a small population of T lymphocytes, representing 
only 1 -5% of T lymphocytes in lymphoid tissue and the circulation. Stressed or 
damaged tissue has been shown to activate y/8 T cells 99. Unlike TH and cytotoxic T 
cells the y/6 T cells recognise antigens without the requirement of a MHC molecule 
or an antigen presenting cell 99. They mainly produce cytokines directed towards TH 1 
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cells, such as IFNy 100 However under certain antigen activation they have been 
shown to produce cytokines for TH 2 activation 99 . 
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3.3.3 THE ROLE OF LYMPHOCYTES IN FRACTURE REPAIR 
A recent literature review concluded that the role of lymphocytes in the fracture 
repair process is insufficiently understood. Recent work from our unit by Gaston et al 
101 investigated fracture repair in Severe Combined Immuno- Deficient (SCID) mice 
which lacked functioning T and B lymphocytes. It was demonstrated that immune 
compromised mice (SCID) when compared to immune competent controls had 
enhancement of bone healing, with stress at yield and stiffness (Young's Modulus) 
being significantly higher. Radiographic analysis revealed significant differences in 
callus area and index at days 7 and days 14 post fracture (p <0.05), with the SCID 
mice gaining callus more quickly. At day 21 the relative bone mineral content was 
significantly higher (p <0.001) in the SCID subjects compared to the immune 
competent controls. Histological analysis of the fracture site at days 1, 3, 7, 14, and 
21 post fracture revealed faster fracture repair in SCID tibiae with more rapid 
progression through cartilage, woven and then lamellar bone formation compared to 
the immune competent controls. 
An in vivo study by Toben et al 102 investigated the absence of lymphocytes on 
fracture repair using a highly specific recombination activating gene 1 knockout 
mouse model (RAG 1 -/ -). These RAG1 -/- mice were deficient in both mature T and 
B lymphocytes. At days 3,7,14 and 21 post fracture they investigated the properties 
of the healing fracture in the RAG 1 -/- mice versus wild type using a combination of 
radiological, mechanical, histological and immunological methods. The results 
demonstrated some interesting findings. The quantitative and qualitative properties of 
the fracture showed a significant lower total callus volume at day 21 in the RAG 1 -/- 
mice compared to wild type (p <0.05). This was confirmed by a greater mineralised 
density on µCT and a significant higher torsional moment on day 21 in the RAG 1 -/- 
mice when compared to controls (p <0.05). Immunological studies further verified 
these observation; less collagen type II and more collagen type X was identified in 
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the RAG1 -/- group compared to controls early in fracture repair. An increased 
number of osteocytes and regulators of osteoblasts and osteocytes, were also 
identified earlier at day 7 in the RAG1-/- mice compared to the controls (p <0.01). 
The overall conclusion of this study was that there was a detrimental role of the 
adaptive immune system in the regulation of fracture repair. 
Overall this was a well designed study, combining histological, radiological and 
mechanical results, however, there were some limitations. RAG1 -/- mice were used 
in this study as Toben suggested they were a cleaner, superior immunological model 
compared to SCID mice 102. This view reflected in vivo studies which showed 
certain SCID mice developed partial immune reactivity, with T and B lymphocytes 
identified in the peritoneal cavity 103. As a consequence certain types of SCID mice 
have been described as `leaky' 103. RAG 1 -/- mice have not been shown to develop 
partial immune reactivity and so were described as `non leaky' 104. Yet studies have 
shown an increase in the number of natural killer cells and the presence of early 
thymocytes, the precursors of T and B lymphocytes, in these RAG 1 -/- knockout 
mice 105,106. These thymocyte cells are difficult to detect but their presence with 
natural killer cells needs to be taken into account in assessing the RAG1 -/- mice 
findings. However as similar effects on fracture repair have been reported in both 
SCID 101 and RAG1 -/ -102 mice this would support the effect on fracture repair being 
linked to the change in T and B lymphocytes. 
Further Toben et al 102 used torsional testing to measure the mechanical strength of 
the fracture. In the living animal, the most common mode of femoral bone failure is 
by bending forces rather than torsion 107. Torsional testing assesses shear forces, 
which are greater at the cortex. In comparison, 4 point bending tests the bending 
forces of compression and tension with sheer eliminated 108. In Toben's study it 
would not have been possible to use the bending strength due to the the presence of 
the intramedullary nail in the femur. Moreover, the results have been expressed as 
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percentages of torsional stiffness. There appears to be no clear evidence of absolute 
values, or mechanical calculations of torsional stiffness. Given that the µCT was used 
to work out callus volume it was not clear if any assumptions were made on the 
shape of the fracture, e.g an ellipse or triangle, so that the torsional stiffness could be 
calculated. 
In all, this small study provided a review of the role of the broad subset of T and B 
lymphocytes in fracture repair. It suggests further investigations into both the innate 
immune system and the selective role of T lymphocyte subtypes in fracture repair are 
required. 
3.3.4 B LYMPHOCYTES IN FRACTURE REPAIR 
B lymphocytes have been identified at the fracture site early in the fracture repair 
process 102. Studies have suggested that they have a regulatory role in osteogenesis 
109,110 Miyaura et al 110 investigated the possible correlation between bone loss and B 
lymphocytes in interleukin 7 (IL7) receptor knock out mice. IL -7 is a cytokine 
produced by bone marrow stromal cells which has been shown in mice to support B 
lymphocyte development 110. Miyaura et al 110 demonstrated an increase in bone 
trabecular volume in the IL7 knock out mice and a reduction in bone trabecular 
volume when IL7 was introduced. Further work by Marusic et al 109 confirmed this 
with a significant increase in new bone formation in mice without functional B 
lymphocytes compared to wild type. 
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3.3.5 T LYMPHOCYTES IN BONE REMODELLING 
Increasingly a number of studies have demonstrated the ability of the T lymphocyte 
to affect bone formation and remodelling. Early in vivo studies showed conflicting 
results; a reduction in bone formation 111, an increase 112 and no difference 113 when 
compared to controls. It was not until the identification of the receptor activator 
nuclear factor -KappaB ligand (RANKL) on activated T lymphocytes that the actions 
of T lymphocytes became clearer. 
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Figure 3: Diagram showing activation of RANKL expression induced in osteoblasts, 
activated T cells, synovial fibroblasts and bone marrow stromal cells, which 
subsequently binds to its specific membrane -bound receptor RANK, thereby 
triggering a network of TRAF- mediated kinase cascades that promote osteoclast 
differentiation, activation and survival. Reproduced from Boyle WJ, Simonet WS, Lacey 
DL. Osteoclast differentiation and activation. Nature 15 May 2003;423:337-342 114 
RANKL is a surface bound protein from the tumour necrosis factor (TNF) cytokine 
family and acts as a ligand for osteoprotegerin (OPGL). Kong et al 115 described the 
regulatory role of RANKL on activate T lymphocytes and osteoclastogenesis, Figure 
3. Their in vitro studies used haematopoeitic bone marrow cells and T lymphocytes 
obtained from the spleen of OPGL -I- mice. In their study the only source of RANKL 
47 
was that bound on T lymphocytes 115. They demonstrated by the presence of 
osteoclast specific markers that T lymphocyte RANKL induced osteoclast activation. 
This observation was reinforced by their in vivo studies where they used a T 
lymphocyte model of rat adjuvant arthritis. In this model RANKL was known to be 
expressed on the T lymphocytes of rats with clinical signs of arthritis. At the onset of 
arthritis the rats were either treated with Osteoprotegerin (OPG), which binds to 
RANKL, or not treated. Those animals that received the OPG had diminished clinical 
signs of arthritis with less cortical or trabecular bone loss, and reduced numbers of 
osteoclasts on histological testing compare to controls 115. Further studies have 
confirmed this role of T lymphocytes on activating osteoclastogenesis and 
stimulating osteoclast activity 116. T lymphocytes are also capable of regulating this 
pathway through the secretion of IFN1 which blocks RANKL- induced 
osteoclastogenesis 117_ 
The importance of T lymphocytes in bone remodelling is particularly relevant in the 
pathology of rheumatoid arthritis. This chronic, auto immune disease causes a 
destructive inflammatory arthropathy, and is defined by the presence of CD4+ T 
lymphocytes and its cytokines in the joint synovium 117 -120. As previously described 
rodent studies using adjuvant arthritis models have demonstrated an increase in 
RANKL mediated bone loss by T lymphocyte activation115. 
As well as their direct action on osteoclastogenesis, T lymphocytes can act 
indirectly via secreted cytokines, particularly Tumour Necrosis Factor alpha (TNF - 
a), figure 4. The pathology of Rheumatoid arthritis can be contributed to TNF -a. 
Alexopoulou et al 121 demonstrated the development of Rheumatoid arthritis in a 
mouse that expressed cell associated TNF -a. Further in vivo mouse studies by 
Redlich et al 122 showed the appearance of TNF dependent bony erosions by 
osteoclasts. TNF -a is known to mediate leucocyte recruitment and activation, 
synovial fibroblast and macrophage activation, increase prostaglandins and matrix 
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metalloproteinase release, besides causing cartilage and bone destruction 123. It has 
been reported that TNF a can act synergistically with RANKL by sensitising 
osteoclast precursors to lower levels of RANKL, leading to earlier activation 124, 
Figure 4. Kobayashi et al 125 have also suggested that they may stimulate osteoclast 
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Figure 4- Proposed schematic ligand receptor mechanism for osteoclastogenesis by T 
lymphocyte. Directly via RANKL or indirectly via TNF -a production.. M- CSF- dependent 
mouse bone marrow macrophages (M -BMM0) differentiate into osteoclasts in the presence 
of macrophage CSF (M -CSF). Nuclear factor a B (NF -a B) and c -Jun NH2- terminal kinase 
(JNK). Osteoclast activation is induced by RANKL and IL -1 through RANK. Adapted and 
Reproduced by Kobayashi K et al. Tumour necrosis factor alpha stimulates osteoclast 
differentiation by a mechanism independent of the ODF /RANKL -RANK interaction.The 
Journal of Experimental Medicine, 191(2), 275 -286. 125 
Support for this important action was provided by studies of the clinical use of anti - 
TNF-a medication in patients with rheumatoid arthritis. A prospective study by 
Ziolkowska et al 119 investigated the effect of infliximab, an anti TNF -ct medication, 
on the elevated levels of serum and synovial RANKL in 43 rheumatoid patients 
compared to 30 healthy individuals. The results showed both a reduction in the levels 
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of serum RANKL, and normalisation of the ratio of RANKL to OPG in patients with 
rheumatoid arthritis119. These clinical studies however had certain limitations. The 
rheumatoid arthritis patients were taking both methotrexate, a steroid, and infliximab 
during the study. Consequently the results could not be attributed solely to the anti 
TNF -a medication. In addition, the elevated levels of RANKL detected in the 
rheumatoid arthritis patients may not actually reflect an elevation in the joint 
synovium, where osteoclastogenesis would be occurring. 
The benefits of anti -TNF -a medication have also been reflected in reported patient 
outcome scores. A multi -centred, prospective clinical trial investigated the effect of 3 
anti - TNF alpha medications on rheumatoid arthritis patient over a year 126. A total of 
770 patients were recruited and allocated to one of 3 anti -TNF alpha medication; 
adalimumab, etanercept or infliximab. Outcomes scores were measured at 3 monthly 
intervals which included, DAS2811 score for disease activity, European League 
Against Rheumatism (EULAR) for disease response, Health Assessment 
Questionnaire ( HAQ) for functional ability, EuroQol 5 dimensions (EQ -5D) for 
quality of life, and the utility, physical and mental components of the Short-Form 
(SF36) score. The results demonstrated a significant overall improvement in the 
physical SF36 score with anti -TNF alpha medication, with a greater statistical 
significance with adalimumab and etanercept than infliximab 126. This short term 
study had limitations. There was no randomisation of patients and the follow up was 
short at 1 year. Of those that started the medication, approximately 20% in each 
group had to stop due to adverse side effects and were commenced on a different 
anti -TNF alpha medication. This cross over of the groups appears not to have been 
taken into account in the analysis of the outcomes. Consequently if a per -protocol 
analysis had been used instead of intention to treat analysis the study may have 
reached different conclusions. 
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A larger multi centred study by Hyrich et al 127 provided further support for the 
benefit of anti -TNF alpha medication in Rheumatoid arthritis. They followed a 
cohort of 11,216 rheumatoid arthritis patients over a 10 year period receiving anti - 
TNF alpha medication 127. They found an overall reduction in the DAS2811 and 
HAQ outcome scores at 6 months and 1 year of medication compared to the pre 
medication baseline. 
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3.3.6 T LYMPHOCYTES IN FRACTURE REPAIR 
In normal fracture repair T lymphocytes have reported to be recruited into the 
fracture site and subsequently to reduce in number with time 82.128. Colburn et al 99 
recently demonstrated the role of a small subset of T lymphocytes, gamma delta T 
cells (SyT), on fracture repair. Using 60 knock out mice, deficient in SyT cells, they 
created a tibial fracture and compared fracture healing by radiographic, histological, 
immunological and mechanical analysis to 60 wild type mice. Their results identified 
a greater expression of bone and cartilage in the SyT deficient group at day 5 post 
fracture compared to wild type. This was also reflected in an increase in fracture 
stability and mechanical strength in the SyT deficient group, 8 weeks post fracture. 
However the mechanical properties of the fracture were measured using 3 point 
bending, rather than 4 point bending. 3 point bending has the disadvantage of 
creating a transverse force which results in an inter -laminar shear stress within the 
testing specimen. This shear stress, absent in 4 point bending, could have lowered the 
point of failure of the bone being tested. Moreover, to identify the degree of 
osteochondral and mature bone formation in the healing fracture they used a scoring 
system described previously by Bos et al129. This scoring system used observational 
criteria from union, spongiosa, bone marrow, and compact bone to determine the 
degree of bone union. This system did not quantify the different tissues present, 
unlike stereology techniques. Observational bias was reduced by blinding the scoring 
observers but the number of observers and the inter observer reliability of this 
scoring system was not reported. 
These results on fracture repair combined with evidence on bone remodelling 
previously suggest that T lymphocytes may control and coordinate fracture healing. 
However the main subtypes of T lymphocytes, Helper (CD4 +) and Cytotoxic 
(CD8 +), have not been studied during fracture repair. This thesis aims to address this. 
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In contrast to the limited published work on the role of the subtypes of T lymphocyte 
in fracture repair the contribution that T lymphocytes make to soft tissue healing has 
been well documented. Lymphocytes have been found in the proliferative phase of 
soft tissue wound healing from day 5, with a peak at day 7 130. The effect of 
lymphocyte deficiency on abdominal wound healing has also been investigated 131. 
Mechanical testing on wounds from immune compromised mice (nude) compared to 
controls showed a mechanically stronger wound from the nude mice up to 2 weeks 
post injury. They concluded that T lymphocytes had an inhibitory effect on wound 
healing 131 Yet, the reduction in wound strength in the nude mice at week 6 
compared to controls implied that T lymphocytes might potentiate the late stages of 
the repair process. In this soft tissue study depletion of all types of T lymphocytes 
was achieved. However as previously described in section 3.3.2 there are 6 
subclasses of T lymphocytes, all with different roles. 
Davis et al 132 looked at depletion of just CD4+ and CD8+ T lymphocytes in wound 
healing . In this study the laparotomy wounds of 24 thymectomised rats depleted in 
CD4 +, CD8+ or both CD4 + /CD8+ T lymphocytes were compared by biomechanical 
testing to controls at 70 days post injury. They showed in rats depleted of CD8+ T 
lymphocytes there was an increase in ultimate strength, resilience and toughness of 
the wound compared to controls. This contrasted in wounds of rats depleted in CD4+ 
T lymphocytes, which had a significant decrease compared to controls. Interesting 
the group depleted in both CD4+ and CD8+ had results intermediate of the CD4+ 
depleted and CD8+ depleted groups but an ultimate strength that was similar to the 
control group. It was concluded that both CD4+ and CD8+ T lymphocytes have 
important, opposing actions in wound healing. CD4+ T lymphocytes might be 
involved in up regulating wound healing while CD8+ T lymphocytes might down 
regulate it 132 
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Overall the Davis et al 132 study was well designed and produced new insights into 
the role of T lymphocytes in wound healing. They did not report on any signs of 
dehiscence or infection of the wounds. Infection is known to delay wound healing 133 
and would reduce wound strength. All the biomechanical results from the 3 different 
depletion groups were only compared to controls using Student's t test. However in 
the conclusion comparisons are made between the groups for which statistical 
analysis should have involved a oneway ANOVA rather than multiple t tests, in order 
to reduce type I error. 
As fracture healing is an example of wound repair, a similar effect of CD4+ T 
lymphocytes on fracture repair has been proposed. Further, it may indicate that 
modulation of the T lymphocyte subtypes may be beneficial in patients with delayed 
bone union and non union. As previously described, the studies by Gaston et al 1 °1 
and Toben et al 102 have highlighted that an abnormality of the immune system due to 
either lack of T and B lymphocytes or perhaps indirect enhancement of the innate 
system resulted in increased mineralization, stiffness and strength of fracture healing. 
Further work by Gaston et al 101 in which the immune system in SCID mice were 
reconstituted using bone marrow from wild type mice, demonstrated that fracture 
repair returned to normal. This indicated that the effect on fracture healing was not 
due to indirect enhancement of the innate system or to an associated genetic defect. It 
was not possible however to differentiate the effects of different subtypes of T 
lymphocytes. 
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4.0 CLINICAL CONDITIONS WITH ALTERED 
IMMUNE SYSTEMS 
4.1 IMMUNODEFICIENCIES 
The importance of the immune system to bone metabolism and fracture healing 
could be indicated by the presence of a musculoskeletal phenotype in patients 
belonging to one of the group of Immunodeficiency diseases. These diseases 
encompass the rare, primary immunodeficiency diseases and the more prevalent 
secondary immunodeficiencies due to infection. The primary immunodeficiencies 
specifically associated with a depletion in T lymphocytes will be reviewed and 
following this the secondary disorders. 
4.1.1 PRIMARY IMMUNODEFICIENCY: DI GEORGE SYNDROME 
DiGeorge, is a primary T lymphocyte deficiency, where there is thymus aplasia or 
hypoplasia leading to a spectrum of immunodeficiency 134. It is a rare condition with 
variation in the reported incidence, from 1 in 3900 to 1 in 9700 live births 135 
Commonly it is caused by a hemizygous deletion at chromosome 22q11.2 region 
which in early embryogenesis affects the development of the 3rd and 4th pharyngeal 
arches 135,136 From these arches, the heart, parathyroid and thymus develop. 
Disorders in these arches results in conotruncal heart defects, neonatal 
hypocalcaemia, and immunodeficiency. 
The character of the immunodeficiency of T lymphocytes varies amongst the 
syndrome. 80 % of patients have `partial' Di George 136, with evidence of low T 
lymphocytes numbers but with normal T lymphocyte proliferation function 137. This 
contrasts to `complete' Di George syndrome who are athymic and have either very 
low levels ( <50 /mm 3) or absence of T lymphocytes 137. Studies measuring the 
thymic function of DiGeorge Syndrome patients have identified a reduced mean or 
median proportion and number of CD3+ and CD4 + T Lymphocytes compared to 
healthy age matched controls 138.139 The immunodeficiency can present at any age 
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but commonly it is identified shortly after birth when the child is being investigated 
for a cardiovascular anomaly 134.135. Older children may present with hypocalcaemic 
tetany and persistent rhinitis, diarrhoea and rashes 134 
The treatment of complete DiGeorge syndrome involves multiple surgical disciplines 
to improve survival. Corrective cardiac surgery is often technically demanding and 
therapies to correct immunodeficiency are challenging. The immune system has to 
reconstituted which can be achieved by cultured, allogenic non HLA thymus 
transplantation 140. After transplantation the host bone marrow thymocytes migrate to 
the transplanted thymus and differentiate into mature T lymphocytes 141. Native T 
lymphocytes have been identified in the circulation 6 -12 months after transplantation 
of the thymus141. Unfortunately the age of the patients in this study were not 
documented141. Although the thymic function can be restored by this transplantation 
the patient remains hypocalcaemic with deficient parathyroid glands. A recent study 
described the transplantation of both thymus and parathyroid in 4 children with 
complete DiGeorge syndrome141. Unfortunately this small case series demonstrated 
that of the 3 surviving individuals 2 developed alloreactivity 141. 
The rare availability of thymus tissue sadly limits its use. Bone marrow 
transplantation is an alternative treatment. Survival rates in a small case series of 9 
patients have been reported to be greater than 75 %, with 2 patients 20 years post 
transplantation 142 
The prognosis of this disease however remains poor. The majority of complete 
DiGeorge cases die in their first year of life due to congenital heart disease or 
infection143,144. There are no reports in the literature of the effects of DiGeorge 
syndrome on fracture repair. The high morbidity caused by the T lymphocyte 
depletion in complete DiGeorge syndrome would be in keeping with an alteration in 
fracture repair. However as most patients have partial DiGeorge syndrome a 
perturbation of fracture repair in this group could have greater clinical implications. 
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4.1.2 SECONDARY DEFICIENCIES 
In Secondary immunodeficiencies there is a secondary factor which is associated 
with the development of immunodeficiency e.g. infection, medication, nutrition. The 
condition of particular relevance include the important and common condition 
Human Immunodeficiency Virus (HIV). 
4.1.2.1 HUMAN IMMUNODEFICIENCY VIRUS 
Immunodeficiency and its effect on osteoimmunology is apparent in infections, such 
as HIV. HIV is a lentivirus, a subset from the family of retroviruses, which have a 
central RNA core surrounded by a capsid and lipid envelope145. The lipid envelope is 
composed of 2 membranes containing 2 glycoproteins, gp41 and gp120. The HIV 
virus infects T lymphocyte and monocytes by the interaction of the gp120 to the host 
cell surface marker CD4+ and a chemokine receptor (either CXCR4 /CCR5). This 
interaction induces the gp41 to bind to heparan sulphate on the host cell membrane. 
This results in the HIV lipid capsule fusing with the cell membrane, allowing the 
capsid to enter the host cell, figure 5. 
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Figure 5: HIV Virus Cycle of infection and replication taken from Chinen J, Shearer WT. 
Molecular virology and immunology of HIV infection. Journal of allergy and clinical 
immunology. 2002;110(2):189 -98. 145 
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There are 2 distinct strains of HIV, Macrophage trophic and T cell trophic, which act 
via different chemoreceptors los. Macrophage trophic use the chemoreceptor CCR5 
to bind to macrophages and primary T cells. In contrast T cell trophic uses the 
CXCR4, which is expressed predominately in CD4+ T lymphocytes 145 Early in the 
HIV infection there is an initial abundance of the macrophage trophic type later on in 
the disease process the T trophic cells appear 145 
After the capsid enters the host cell the viral RNA genome and proteins are released 
into the cytoplasm, figure 5. The viral RNA is then reversed -transcribed into 
complementary DNA (HIV c 1 DNA) and transported into the nucleus where it 
becomes randomly incorporated into the hosts DNA. The DNA is then transcribed 
into viral RNA and cleaved by the enzyme protease, forming new virions 146 
HIV is a viral infection characterised by a progressive reduction in CD4 +T 
lymphocytes levels. HIV infection has been defined by the World health Organisation 
(WHO) as " An individual with HIV infection irrespective of clinical stage (including 
severe or stage 4 clinical disease, also known as AIDS) confirmed by laboratory 
criteria according to country definition and requirements" 147. Diagnosis in adults and 
children over 18 months requires a positive HIV antibody test, confirmed by a 
second HIV antibody test which relies on the detection of different antigens, and/or a 
positive virology test for HIV or its components147. Once HIV infection has been 
confirmed the disease is then divided into clinical stages I -IV. Table II describes the 










Mild Moderate ( <10% loss) Body weight 
Recurrent Respiratory Tract Infections 
Herpes Zoster, Recurrent oral ulcerations, 
Papular pruritic eruptions, Seborrhoeic 
dermatitis, Fungal nail infections 
2 
Advanced Unexplained* weight loss >10% Body weight 
Unexplained* Chronic Diarrhoea >1 month 
Unexplained* persistent fever >37.6oC 
Persistent oral Candidiasis 
Oral hairy leukoplakia 
Pulmonary tuberculosis 
Severe bacteria Infections 
Acute Necrotizing ulcerative stomatitis, gingivitis 
or periodontitis 
Unexplained anaemia ( <8g /di), neutropenia 
( <0.5x 109 per litre) or chronic thrombocytopenia 
( <50x 109 per litre) 
3 
Severe HIV wasting syndrome 
Pneumocystis pneumonia 
Recurrent severe bacterial pneumonia 




Central nervous system toxoplasmosis 
HIV encephalopathy, Lymphoma, invasive 
cervical carcinoma, Chronic isosporiasis, 
Disseminated non -tuberculous mycobacterial 
infection 
Atypical disseminated leishmaniasis 
Progressive multifocal leukoencephalopathy 
Chronic crytosporidiosis 
Symptomatic HIV associated neuropathy 
4 
Table II: the WHO Clinical staging of HIV infection, *unexplained refers to where the 
condition is not explained by other causes 147 
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These clinical stages of the HIV infection are used in combination with the 
laboratory levels of CD4 +T lymphocytes and plasma HIV -1 RNA viral load to 
determine disease progression, table III 148. In general as the disease progresses there 
is a reduction in the levels of CD4+ T lymphocytes with a subsequent increase in 
plasma viral load 148,147. The normal absolute count for CD4+ T lymphocytes in 
adolescents and adults is between 500 to 1500 cells per mm3 of blood 147. Clinically 
this CD4+ count remains important for assessing the effectiveness of anti -retroviral 
treatment with an increase in CD4+ levels observed after a few months of 
commencing the medication 147. 
HIV Associated 
Immunodeficiency 
>5 years (absolute numbers per 
mm3 or %CD4 +) 
None or not significant >500 
Mild 350 -499 
Advanced 200 -349 
Severe <200 or <15% 
Table Ill: WHO immunological classification for established HIV infection 147 
HIV infection depletes effective CD4 +Lymphocytes by a combination of 
mechanisms; impaired function, impaired production and induction of apoptosis 145 
In general the immune system responds to the CD4+ depletion initially by the 
stimulation of specific CD8+ cytotoxic T lymphocytes, to control the HIV infection 
145. Yet, as the disease progresses both the numbers of CD8+ T lymphocytes and 
their cytotoxic effect on HIV replication are reduced 149. B lymphocytes' production 
of antibodies, both T lymphocyte dependent and independent are also reduced. There 
is also a reduction in overall B lymphocyte number 15°. To compensate for the 
depleted CD4+ lymphocytes the CD4 progenitor cells in the thymus, bone marrow 
and lymphoid tissue are released and progressively diminish the T lymphocyte stores 
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within these tissues until a level where opportunistic viral infection can no longer be 
resisted ( <200 cells /mm3) . This compensation mechanism then fails and eventually 
the immune system collapses. 
The immunodeficiency of T lymphocytes in HIV infection is reflected in reduced 
resistance to infection as well as alterations in bone metabolism. Cross sectional 
studies have shown an increase prevalence of osteopenia and osteoporosis in HIV 
infected patients compared to normal controls 151. Knobel et al 152 described a 
prospective cross sectional study of bone mineral density of 80 HIV infected patients 
(58 males, 22 females) compared to a seronegative, age and gender matched control 
group. 26 of the 80 patients were not on high active anti -retroviral therapy (HAART) 
compared to 37 who were. Using dual energy x -ray absorptiometry (DEXA) the bone 
mineral density (BMD) of the femur and lumbar spine were measured and quantified 
by T and Z scores. T score being a standard deviation in BMD from the mean for a 
population at age 30, and Z score representing a standard deviation in BMD within 
the mean of the same age and sex group. The patients were then classified by their T 
score into normal, osteopenic or osteoporotic groups using the WHO definition of 
osteoporosis. They found a lower BMD in HIV infected patients in the femur and 
lumbar spine compared to age matched controls (p <0.001). Osteoporosis was also 
more prevalent, 21.2% in the HIV infected patients compared to 5% in normal 
controls (p <0.00009). Interestingly there was no correlation between HIV stage, viral 
load, CD4+ count or duration of HAART with osteoporosis. Though this was a small 
study the methodology was robust and supported a correlation between HIV 
infection and osteoporosis independent of anti retroviral treatment. 
A reduced BMD and osteoporosis is recognised as a leading cause of fragility 
fractures 153. HIV infected patients are therefore at increased fracture risk 154 
As already discussed in section 3.1.2 fracture repair involves an initial inflammatory 
response with the local release of pro- inflammatory cytokines such as TNF alpha, IL- 
1, IL -6 , Insulin like growth factor (IGF -1). IGF -1 initiates the cytokine cascade and 
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integrates the innate and the adaptive immune systems. Studies have shown an 
increase in the cytokines TNF alpha and IGF -1 in HIV infection compared to normal 
controls'55 "56. Yet, the effect of this on fracture repair can only be speculated. It is 
not known whether an increase in baseline levels of TNF alpha lead to an up 
regulation of the fracture repair process or conversely, a desensitisation or depletion 
of fracture repair leading to non -union 154 
Concerning the issue of whether the immunodeficiency of HIV infection affects 
fracture healing, there are only a few clinical studies. A prospective study by Kamat 
and Govender 157 investigated the effect of HIV infection on distal tibial fracture 
repair. In this study 2313 Weber B distal tibia fractures without talar shift were 
identified from radiographs and subsequently divided into groups by HIV status and 
WHO staging; 829 HIV negative patients, 729 HIV positive patients (Stage I -III) and 
755 HIV positive patients (Stage IV). All the patients were in the same age range, 
socioeconomic status and were treated conservatively in a weight bearing cast. 
They observed no significant difference amongst the fracture union rate between the 
HIV positive stage I -III patients compared to the control group. Interestingly they did 
find a delay in fracture repair in the HIV stage IV group, with a significant increase 
in fracture non union (12.45 %) compared to controls (1.5 %) and HIV stage I -III 
(1.26 %). This study though important has some limitations. The study defined 
fracture union but it failed to define non union clearly. It is not reported whether the 
observers were blinded nor if any inter observer error was taken into account. It was 
also unclear if any patient was on high active anti -retroviral therapy (HAART). This 
would be important as a link between one type of HAART, tenofovir, and a reduced 
BMD has been reported 158. However, this observation does not completely explain 
the alterations in bone remodelling as HIV positive patients not taking HAART have 
evidence of reduced bone remodelling 159. This infers that HIV infection itself has a 
role in bone remodelling and repair 159 
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The potential risk of delayed union and HIV has important clinical implications 
particularly in Sub -Saharan Africa where the incidence of HIV and road traffic 
related fractures continues to rise 160. Frequently the fractures are open, making 
surgical treatment options more complicated in a resource depleted environment. The 
mainstay of treatment of open fractures involves early radical debridement, 
stabilisation of the fracture and the use of broad spectrum antibiotics. Complicated 
by poor road transport and inadequate medical services few patients receive this 
treatment. Instead many of these patients present late to the referral hospitals with 
severe infection and fracture non union or malunionl60. 
Wound infection remains the main complication in the young HIV patients post 
surgery with stage I or II disease 16o A recent prospective epidemiological 
observational study by Aird et al 161 investigated the risk of wound infection in 133 
patients (33 HIV positive) with open fractures treated by closed and open surgical 
methods. They found that the more advanced the HIV grade the greater risk of 
wound infection compared to both HIV negative and lower grade HIV positive 
patients 161. When looking closer at the infection rates in HIV positive and negative 
patients with different wound grades they also found an association. In grade I open 
fractures the more advanced the HIV grade the greater the risk of wound infection 
(risk ratio= 6.33, p= 0.02) 161. This observation was thought to be related to the delay 
in surgical treatment of these open grade I fractures 161. However as the HIV negative 
patients' surgery was also delayed the result could be explained by the HIV disease 
itself, with a reduction in number and dysfunction of CD4+ T lymphocytes. 
Combined with a depletion and dysfunction of CD4+ lymphocytes the ability of a 
fracture to unite maybe impaired, leading to a higher risk of non union. A small 
observational prospective cohort study where assessors where blinded to HIV status 
compared 7 HIV patients (WHO stage 0 -2) with open tibial fractures to 20 HIV 
negative controls in Malawi 162. At 3 months results showed a significant difference 
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between the groups; 2 fractures had healed and 5 were infected in HIV positive group 
compared to 17 healed and 4 infected in the HIV negative group (p= 0.020). At 6 
months 43% HIV patient had non union of fracture compared to 5.9% of HIV 
negative patients (p= 0.059). Although a small study, it highlighted the increased risk 
of fracture non union in HIV positive patients. Whether this was secondary to 
infection, HIV therapy or directly as a result of the HIV infection's effect on the 
immune system was not answered. 
The socioeconomic burden of treating HIV positive patients with fractures is 
potentially huge, and is compounded by the possible increase in fracture non union. 
Further work is therefore needed to investigate the effect of CD4+ lymphocytes on 
fracture repair. This could be of great benefit in relieving some of this socioeconomic 
burden. 
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4.1.2.2 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic, systemic auto immune disease that has been 
estimated to affect 1.16% of women and 0.44% of men over 18 years in the UK 163 
There is a peak incidence between the ages of 35 -55 years, although it can occur at 
any age. Classically patients complain of morning joint stiffness lasting more than an 
1 hour, soft tissue swelling, subcutaneous nodules and symmetrical swelling around 
3 or more joints specially the proximal interphalangeal, metacarpophalangeal, or 
wrist joints 164. Patients are diagnosed usually based on the presence of 4 or more 
symptoms present for at least 4 -6 weeks 164. More recently diagnostic criteria have 
been developed by the American College of Rheumatology /European League 
Against Rheumatism classification criteria, table IV 165. A score of 6/10 or greater is 
indicative of the presence of rheumatoid arthritis if other diseases have been 
excluded. 
The aetiology of RA remains unknown but many factors may alter the immune 
system in an immune susceptible host. Genetics are considered to have a role 166 
Identical twins have been shown to be three to four times more likely to be 
concordant with the disease than non identical twins 166. Infection particular Epstein - 
barr virus (EBV) has long been implicated as a causative agent 164. Studies have 
demonstrated the presence of antibodies to EBV specific antigens in 90% of RA 
patients 167. Autoimmunity plays a pivotal role in the disease process which has been 
confirmed by the in vitro identification of autoantibodies in RA patients 168. 
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Criteria Score 
A Joint Involvement 1 Large Joint 0 
2 -10 Large Joints 1 
1 -3 Small Joints 2 
4 -10 Small Joints 3 
>10 Joints 5 
B Serology Negative RF and 
ACPA 
0 
Low Positive RF or 
ACPA 
2 
High Positive RF or 
ACPA 
3 
C Acute Phase 
Reactants 
Normal CRP & ESR 0 0 
Abnormal CRP or 
normal ESR 
1 
D Duration of 
symptoms 
< 6 weeks 0 
> 6 weeks 1 
TOTAL /10 
Table IV: The 2010 American College of Rheumatology /European League Against 
Rheumatism classification criteria for Rheumatoid Arthritis 165. RF, Rheumatoid factor; 
ACPA, anti- citrullinated protein antibody; CRP, C- reactive protein; ESR, erythrocyte 
sedimentation rate estimated 
Both T lymphocytes (particularly Tregs) and cytokines have been reported as being 
pivotal in the pathogenesis of rheumatoid arthritis 118.119 121. Animal studies have 
provided firm evidence that Treg lymphocytes can be stimulated in vitro to suppress 
the proliferation of effector T cells and inhibit cytokines169. A reduction in Treg 
numbers in the peripheral circulation has been found in animals genetically prone to 
autoimmune diseases such as diabetes 17°. Whilst addition of Tregs to an animal 
model of multiple sclerosis has been shown to prevent experimental autoimmune 
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encephalitis (EAE) 171. These studies support the observation that Tregs have a role 
in regulating autoimmune diseases. 
In Rheumatoid arthritis in vitro studies using Tregs from patients with active RA 
have shown similar results 169. Van Amelsfort et al 172 reported a smaller percentage 
of Tregs in the peripheral blood (PF -17%) compared to the joint synovial fluid 
( SF -26%) in patient with active RA172. Both these values were significantly greater ( 
p <0.0001) than the number of Tregs found in the peripheral blood of healthy 
individuals (11 %) 172. It has been reported that this increase in SFTregs involved the 
chemoreceptor CXCR4 169. Treg specifically express CXCR4, and the ligand for 
CXCR4 is thought to be persistently expressed on joint synovial endothelial cells 173. 
As a consequence the Tregs were probably recruited and retained within the 
synovium 169. 
Interestingly, differences have been found between the phenotype of the Tregs from 
the PB and SF in patients with Rheumatoid arthritis. VanAmelsfort et al 172 found 
the SF Tregs display a more active phenotype, with greater expression of regulatory 
molecules compared to the PB Tregs from RA and normal individuals 172. 
Functionally they also differed, with the SFTregs showing a greater suppressive 
functional activity 172. However other studies disputed these finding. Ehrenstein et 
a1174 showed PB Treg's isolated from patients with active RA were unable to inhibit 
the cytokines produced from effector T lymphocytes or monocytes. Interestingly this 
function was restored once the patient was given 3 months treatment of anti TNF 
alpha medication 174. Thornton et al described similar findings with inhibition of 
Treg's function by synovial cytokines, specifically IL -2 and IL -7 175. 
Rodent models of RA considered TH1 lymphocytes and their pro inflammatory 
cytokines (IFNy,TNF) to mediate the disease 176. Yet recent studies have implicated 
the TH17, a subpopulation of T lymphocytes and its cytokine IL -17 177. In this well 
designed study Chabaud et al 178 measured the production of IL -17 from RA, 
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osteoarthritis (OA) and normal healthy synovial tissue cultured ex vivo. IL -17 
production was found to be higher in the RA synovium (41.7 units) compared to OA 
(5.3 units) or normal controls (zero) 178. This was also confirmed by IL -17 mRNA 
detection on Southern blot analysis. These observations have been supported by 
further studies which have shown accelerated collagen induced arthritis in mice 
deficient in TH 1 mice 179.180. Yet, additional studies are required to identify the 
function of TH17 and IL -7 in the pathogenesis of RA. 
Recent studies have reported an oligoclonal increase in CD8+ T lymphocytes in the 
PF and SF in RA patients, compared to normal individuals 181.182. Cho et al 183 further 
identified that the number of CD4+ T lymphocytes in RA patients was significantly 
less in the SF rather than the PF (29.8 ± 14.1 vs. 35.9 ± 8.7, p 0 0.072). As a 
consequence the ratio of CD4+/CD8+ T lymphocytes was significantly lower in the 
SF (0.85 ± 0.45) than in the PF from RA patients (2.10 ± 1.08, p 0 0.003) and healthy 
controls (1.89 ± 1.31, p 0 0.009) 183. In addition they also observed that CD8+ T 
lymphocytes were inversely correlate with RA disease activity levels. On closer 
review they found the synovial CD8 +T lymphocytes were early differentiated, more 
active and less cytotoxic, producing more IL10 suppressor T lymphocytes 183. They 
suggested that CD8+ T lymphocyte had an immuloregulatory role in RA pathology 
183. This regulatory role has been supported in mice studies using experimental 
allergic encephalomyelitis (EaE), a animal model of human multiple sclerosis 184. 
Jing et al 184 found that mice depleted in CD8+ T lymphocytes had a greater 
susceptibility to EaE after a second exposure to EaE compare to undepleted controls. 
Therapeutic approaches to modulating T lymphocytes have shown that T 
lymphocytes are involved in the pathogenesis of RA185 , as previously described in 
section 3.2.5. Benefits have been observed in RA patients who have received 
treatment with abatacept 186, a recombinate fusion protein which selectively 
modulates the CD80 or CD 86 -CD28 co- stimulatory signal required for full T cell 
activation. However treatments with cyclosporins, CD4 specific antibody, CD52 
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specific monoclonal antibody, alemtuzumab, have been disappointing 187 and 
suggested that the pathogenesis of RA is not exclusive T lymphocyte driven. 
T lymphocytes have been reported to directly interact with fibroblasts and 
macrophages via cell membrane contact 188. Once activated these macrophages 
release IL -15 and TNF a.188. Mcinnes et al 188 have suggested that this leads to a 
positive feedback mechanism seen in RA; more T lymphocytes are activated by 
IL -15, which in turn activates more macrophages and produces more IL -15 which 
activates more T lymphocytes, leading to an inflammatory cascade. 
Evidence is well established for the importance of cytokines in the pathogenesis of 
RA. Low concentrations of cytokines IL -17, IL -1 and TNF a. have been shown to 
have a synergistic effect on synovial fibroblasts, causing activation, cytokine release 
and enhancing the inflammatory cascade 185. IL -17 had also been reported to drive 
neutrophil differentiation, maturation, activation and cytokine release185. In addition 
IL -17 can also activate monocytes and macrophages. IL -6 and IL -23, cytokines 
produced by TH17 lymphocytes have been reported to promote skin inflammation 
and are associated with modulating cutaneous acanthosis 189. 
It is not only the presence of cytokines which have been implicated in the 
pathogenesis of RA but also a reduction or deficiency 185. T lymphocytes cytokines, 
IFNy, IL -2 and IL -4 are at low frequencies in the SF of RA patients and are 
frequently only detected at protein and mRNA levels 188. Synovial membrane 
cytokines, IL -10, IL -11 and and IL -1 receptor antagonist (IL -rla), are produced at 
such low concentrations that they are unable to prevent mediation of counter 
regulatory activation against the dominant pro- inflammatory cytokines IL -1 and TNF 
a 190. It has been speculated that this reduction of immunoregulation maybe one of 
the many factors in the pathogenesis of RA 190. 
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The pathophysiology of RA commences with initial inflammation of the joint and 
evidence of soft tissue hypertrophy. Histology reveals the synovium lining to be 
thickened with infiltration of fibroblasts and monocytes, figure 6 168. The synovium 
continues to proliferate and undergo angiogenesis becoming thickened with 
granulation tissue, known as a pannus, which invades the articular cartilage 191. The 
pannus fibroblasts and monocytes are replaced mainly by CD4 + lymphocytes but 
also smaller numbers of CD8 + T lymphocytes, B lymphocytes, macrophages and 
plasma cells 191 
Thickened synovium 
Figure 6: A photomicrograph (magnification x200) of the synovial lining in RA 
showing the thickened folds of synovium with infiltration of inflammatory cells. 
Reproduced from Firestein G, Evolving Concepts of rheumatoid Arthritis, Nature 
2003: 423;356 -361 
These cells release inflammatory cytokines particularly TNF alpha, IL -1 and IL6 
which through their cytotoxic action on chondrocytes, destroys articular cartilage 191. 
Combined with activation of osteogenesis, as previously described, periarticular bone 
is then eroded, leading to irreversible joint damage. 
The treatment of RA aims to target the inflammatory cascade and cytokine 
production. Analgesia in the form of non steroidal anti -inflammatory medication 
aims to reduce inflammation, pain and aid mobilisation. Second line medication 
includes methotrexate and sulphasalazine which slowly reduce the pain and 
inflammation over weeks by possible suppression of T lymphocyte activation. 
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New biological therapies such as anti -TNF alpha, as previously described, target 
cytokine production and are now routinely used in patients who fail adequate 
response with second line medication. For those in whom disease progresses to 
irreversible joint damage, surgery in the form of soft tissue release, synovectomy or 
total joint replacement can relieve pain and aid mobilisation. 
Patients with RA have an increase risk of osteoporotic fractures. One of the largest 
retrospective studies of 30,262 RA patients identified 2,460 fractures over a 7.4 year 
period 192. Compared to controls they identified a marked increase in hip fracture 
( RR 2.0 95% CI 1.802.3 ) and spinal fracture ( RR 2.4 95% CI 2.0 -2.8) 192. The 
increased risk was multifactorial but associated with a greater than 10 year history of 
RA, a low basal metabolic index and the use of glucocorticoids 192. This increased 
fracture rate combined with the complexity of the disease process suggests that 
Rheumatoid arthritis patients are an important subgroup of patients for which the 
Orthopaedic surgeon may need to observe closely or treat differently when they 
sustain a fracture. 
Although evidence exists for an increase in fracture rate the subsequent behaviour of 
the fractures has not been reported, yet, this may be perturbed in association with the 
altered T lymphocyte function in Rheumatoid arthritis patients. This thesis aims to 
address this by investigating the risk of fracture non -union in an in vivo mouse 
fracture model with a perturbed immune system. 
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5.0 AIMS, OBJECTIVES and HYPOTHESIS 
The overall aim of this study was to investigate whether animals with perturbed 
lymphocyte function have abnormal bone fracture repair. 
This was evaluated by preclinical studies to test the hypothesis that T lymphocytes 
have a major role in bone fracture repair, specifically CD4+ T lymphocytes are 
advantageous and CD8+ T Lymphocytes are inhibitory to fracture repair., 
The null hypotheses tested were: 
1) There was no difference on the fracture repair process in animals who had been 
depleted of CD4+ and CD8+ T lymphocytes. 
2) There was no difference on the fracture repair process in animals who had been 
depleted of CD4+ T lymphocytes compared to immune competent controls. 
3) There was no difference on the fracture repair process in animals who had been 
depleted of CD8+ T lymphocytes compared to immune competent controls. 
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5.1 IN VIVO STUDIES 
The overall aim of the in vivo study was to investigate the role of CD4+ and CD8+ T 
lymphocytes in normal fracture repair using an established model of depletion of 
CD4+ and CD8+ lymphocytes in constitutionally immune competent (wild type) 
mice. More specifically 
1. To generate in vivo a controlled depletion of T lymphocyte subtypes over a 
specific period of time. 
2. To monitor the progress of the bone repair process at both the histological and 
functional (mechanical) level and to relate this to T lymphocyte status. 
The overall question in the in vivo study was 
`What was the involvement of CD4+ and CD8+ T lymphocytes in bone fracture 
repair? 
Specific questions in the in vivo study were 
1.To what extent does depletion of CD4+ or CD8+ T lymphocytes influence the 
mechanical properties of the fracture repair regenerate tissue? In particular the bone 
strength of the fracture repair regenerate tissue. 
2. To what extent does depletion of CD4+ or CD8+ T lymphocytes alter the 
morphology and tissue heterogeneity of the fracture repair regenerate tissue? 
From the evidence of wound healing132 that exists I hypothesise that 
A) T lymphocytes have a major role in fracture repair 
B) CD4+ T lymphocytes have a beneficial role in fracture repair 
C) CD8+ T lymphocytes have an inhibitory role in fracture repair 
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6.0 METHOD AND MATERIALS 
75 
6.0 METHODS AND MATERIALS 
6.1. DEPLETION OF MURINE CD4+ AND CD8+ T LYMPHOCYTES 
6.1.1 ANIMAL MODEL 
For the entire thesis the mice used were all male wild BALB -c mice, aged 6 -8 weeks 
old (Charles Rivers Laboratory, UK), maintained in the Biomedical Research 
Resources, University of Edinburgh, Little France. All work was carried out with an 
appropriate home office licence. The mice were chosen at 6 -8 weeks old as in the 
murine model 6 weeks was considered to equate to a young adult in humans. 
6.1.2 DEPLETION OF T LYMPHOCYTES 
The depletion of T lymphocytes was conducted using the following monoclonal 
antibodies Table V, obtained as cell line stocks from European Collection of Cell 
Cultures (ECACC), Porton Down, UK and then grown by ImmunoSoly ®, University 
of Edinburgh. Prior to their use, each antibody was tested by ImmunoSolv® against 
BALB /c thymocytes and splenocytes by indirect immunofluorescence, to confirm its 
binding capacity to T lymphocytes (Appendix 1). AFRC MAC 51 showed no binding 
ability to T lymphocytes whilst YTS 169.4.2.1 Anti -Lyt -2 and YTS 191.1.1.2 Anti - 


















IgG2b Anti- phytochrome 85060405 Control Antibody 
Table V: The Cell line and the derived Antibodies used in the depletion experiment 
These antibodies were chosen as they had previously been used in immunological 
studies by our unit 193. AFRC MAC 51 was chosen as the control as this antibody 
acted on phytochrome, a photoreceptor plant pigment not present in animals. 
Following 1 week of acclimatisation each healthy BALB -c male mouse was injected 
with 0.15 mls of 50µg of the relative antibody (Table V) in 100µg of PBS. Injections 
were performed on days 0,1,2, and 7,8,9 (figure 6). These days were chosen to allow 
time in between the injections for the mice to recover from the antibody depletion 
effects. 
5 mice from the same injection group were kept in a cage together and ear marked 
for identification purposes. The environment the animals were exposed to was 
standardised for 1) temperature, 2) the amount of artificial light, 3) clean air, 4) dry 
food and 5) water source. The mice were weighed daily to monitor their health. 
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6.1.3 SPLEEN EXTRACTION 
The details of the spleen extraction protocol are described below. 
The mice (n =5 in each group) were kept until day 16 when they were killed using 
CO2 inhalation and their spleen harvested and placed in sterile PBS. Day 16 was 
chosen as this would be the day in future experiments when the tibial fracture would 
be created. Depletion of CD8+ and CD4+ T lymphocytes was assessed at this time 
point. All 15 spleens were prepared immediately for Flow assisted cell sorting 
(FACS) by firstly labelling the splenic CD8+ and CD4+ T lymphocytes present. 
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6.2 LABELLING OF MURINE CD8+ and CD4+ T LYMPHOCYTES 
This protocol was adapted from the Standard Operating Procedure written by 
Melanie Leech, Immunobiology Group, MRC Centre for Inflammation Research, 
University of Edinburgh. 
Before the T lymphocytes could be labelled, a single cell suspension had to be 
created, this will be described below. 
6.2A CREATION OF A SINGLE CELL SUSPENSION 
Wash media was prepared by combining Sterile PBS with FCS to a concentration of 
10 %. A 40 pm sieve was placed into a small petri dish for each spleen. The spleen 
and media were transferred into the sieve and using a 1 ml rubber tipped plunger, 
gently pushed through. The sieve was then removed and discarded. The suspension 
was then transferred into a clean 15 ml tube and filled to 15 mls with PBS with FCS/ 
wash media. The cells were then pelleted at 300 xg /5min/4oC (1200rpm) using an 
ultracentrifuge. After removing the tubes the supernatant was poured out and the cell 
pellet resuspended into the remaining solution using a pipette. Red cell buffer was 
prepared using 1mM of ammonium bicarbonate and 114mM of ammonium chloride. 
5 mls of red cell lysis buffer was added using the pipette and the solution incubated 
on ice for 5 minutes. The tube was then filled with wash media/PBS with FCS to 15 
mls, to soak up chloride ions and prevent further cell lysis. The cells were then 
pelleted at 300 xg /5min /4 °C (1200rpm). The supernatant was discarded and the cells 
resuspended. The remaining solution was made up to 5 mls by adding wash media/ 
PBS with FCS, creating Solution A. Solution A was now ready for cell counting. 
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6.2.2 COUNTING CELLS 
Initially 901.1L of Trypan Blue was added into a small 1.5 ml bijou. 10 µL from the 
single cell suspension solution A was added to the bijou to create mixture B. A 
haemocytometer was removed from the alcohol bath and dried. A dry coverslip was 
firstly breathed on, and then slid onto the haemocytometer to create a vacuum. 10 
mixture B was removed by pipette and injected onto the slide of the 
haemocytometer. Using the x20 lens on the light microscope (Zeiss Axio Imager Al, 
Carl Zeiss Ltd, United Kingdom), the grid was brought into focus. Cells with a halo 
appearance were then counted and blue, dead cells ignored. Cells were only counted 
if they were within the square or touching 2 sides of the square, the right and bottom. 
Cells touching the left and top lines of the square were ignored. 
Once counted the CD4+ and CD8+ T lymphocytes had to be labelled for detection by 
FACS. This method will be subsequently described 
6.2.3 LABELLING OF CD4+ and CD8+ T LYMPHOCYTES 
The following materials were prepared prior to commencing the protocol; 
Wash media: PBS Sterile with FCS= 10% FCS 
FACS wash: 500m1 PBS without Calcium & Magnesium, 0.2% BSA (Sigma - 
Aldrich), 0.1% Sodium Azide (Sigma- Aldrich) 
FACS Fix: 475m1 PBS without Calcium & Magnesium, 25 mis 40% Formaldehyde 
PBS: PBS without Calcium and Magnesium 
ANTIBODIES: CD4 FITC (Catalogue No 5503046) 
CD8 PE (Catalogue No 553033 
Isotype PE (Catalogue no 553930) 
isotype FITC mouse IgG2a (Catalogue No 553456) 
10 mls of complete wash media was added to each tube containing solutions A. 
Cells were then pelleted at 300 xg/5min/4 °C (1200rpm) and the supernatant 
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discarded. The cell pellet was then resuspended in FACS wash at 1 x 106 cells per ml 
and 100 µL (1x106 cells) was then transferred to a 96 well plate. The cells were then 
pelleted at 300 xg /5min/4 °C (1200rpm), the supernatant removed and 100 pL of 
FACS wash containing 1µg FcR block/ 1x106 cells was then added to each well. The 
wells was then incubated in the dark for 15 mins at 4 °C in a standard fridge. After 
incubation antibody (CD4 FITC/ CD8 PE/ isotype PE/ isotype FITC/ CD4 FITC & 
CD8 PE or no stain) was added to each well. The wells were further incubate in the 
dark for 30 mins at 4 °C and the cells pelleted at 300 xg /5min/4 °C (1200rpm). The 
supernatant was shaken off and 200 pL of FACS wash was added to each well. The 
cells were then pelleted again at 300 xg/5min/4 °C (1200rpm) and the supernatant 
shaken off. 200 pL of FACS wash was then added to each well and the cells pelleted 
for a third time at 300 xg /5min/4 °C (1200rpm). The supernatant was again removed 
and the cells resuspended in 100 µL PBS and 100 pL FACS fix. 200 µL of each 
single cell solution from each spleen sample was then pipette into FACS tubes. 
6.2.4. CONFIRMATION OF T LYMPHOCYTE DEPLETION BY FACS 
To confirm the depletion of CD4+ and CD8+ T lymphocytes by antibodies in the 
CD4+ and CD8+ depleted group FACS was used. Once CD4+ and CD8+ T 
lymphocytes had been labelled as previous described section 2.1.4, the 6 FACS tubes 
from each of the 15 murine single cell spleen suspensions were then sorted through 
the FACSCalibur machine (Becton Dickson, San Jose, USA) with the standard filter 
and the system standardised. 
The number of CD4+ and CD8+ T Lymphocytes present in each of the 3 murine 
groups, control, CD4+ depleted and CD8+ depleted was recorded. 
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6.3 DEPLETION OF MURINE CD4+ AND CD8 +T LYMPHOCYTES IN A 
MOUSE FRACTURE MODEL 
6.3.1 ANIMAL MODEL 
The same animal model was used as previous described in section 6.1.1. 
6.3.2 DEPLETION OF CD4+ AND CD8+ T LYMPHOCYTES 
The protocol for depletion of CD4+ and CD8+ T Lymphocytes was repeated as 
previously described in section 6.1.2 for n =15. 
6.3.3 THE OVERALL METHOD PROTOCOL 
The overall protocol is summarised in figure 7 and subsequently below. 
On day 16 after the depletion phase the tibia fracture was created in each group. 
Post fracture 4 mice were killed at day 23 (day 7 post fracture), day 30 (14 days post 
fracture) from each group, Figure 7. Each mouse was used to confirm depletion of 
the lymphocytes, and also for histology and immunology testing. 7 mice were killed 
at day 37 (21 days post fracture) from each group. From each group the tibia was 
harvested from 6 of these 7 mice tibia were tested mechanically by 4 point bending. 




DAYS POST FRACTURE 14 
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5 4 4 1 
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Figure 7:Timeline Diagram of the overall experiment 
6.3.4 FRACTURE MODEL 
A closed right tibia fracture was created in each mouse on day 16 of the experiment, 
figure 7. This time point was chosen as the depletion study had confirmed depletion 
of both CD8+ and CD4+ T lymphocytes at this time point. Prior to creation of the 
closed tibia fracture the mice were anaesthetised and given analgesia, for which the 
protocols will now be described. 
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6.3.5. ANAESTHESIA 
The mice were weighed (grams) then placed in an anaesthetic chamber. 3 -5% of 
isoflurane was used to induce anaesthesia. The remaining isoflurane was absorbed by 
activated charcoal. Isoflurane was chosen as the anaesthetic agent as it gave a rapid 
induction and quick recovery with less profound side effects than halothane, 
particularly cardiovascular depression. The level of anaesthetic depth was measured 
in the mouse by the absence of movement, the absence of withdrawal reflexes (toe 
pinch) and the pattern and depth of respiration. Once the mouse was fully 
anaesthetised they were transferred to the fracture apparatus with isoflurane at 1 -2% 
to maintain anaesthesia. 
6.3.6. ANALGESIA 
Prior to fracture creation, whilst under general anaesthetic, 0.05mg/kg of 
Buprenorphine (Vetergesic) a semi synthetic opioid analgesic was given 
subcutaneously. As the mice were below 100g body weight 0.1m1 of Buprenorphine 
( 0.3mg /m1) was diluted in 0.9ml sterile water for injection. The administered volume 
was was chosen as per chart X, See Appendix 1. Buprenorphine was chosen as 
analgesia as it had been an effective in previously studies in our unit 194 
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6.3.7 CREATION OF TIBIA FRACTURE 
The tibial fracture was created using a Bourque apparatus, which had been 
successfully used in our unit and by others to reliable reproduce closed tibial 
fractures 194,195 The protocol is described below. 
The mouse was maintained under general anaesthesia throughout the whole 
procedure by gaseous anaesthesia of isoflurane 1 -2% via an inhalation funnel, figure 
8. 
The mouse was then placed on an adjustable foam support adjacent to the fracture 
apparatus. 1 -2 mls of warm saline was then given subcutaneously to the mouse to 
maintain body temperature prior to tibial fracture creation. 
The right hind leg was shaved and the tibia palpated so that the anterior aspect of the 
leg was facing away from the operator of the apparatus. The hind leg was then placed 
carefully in this orientation into the Bourque apparatus with the fibula in the gap of 
the fulcrum, figures 8 and 9. This orientation was important to prevent simultaneous 







Figure 8: Cadaveric mouse in Bourque apparatus, taken by Mr M Gaston 
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Figure 9: Cadaveric mouse in Bourque apparatus showing position of tibia taken by Mr 
M Gaston 
Head -Tuberosity 
Fibula - Crest of tibia 
Shaft of tibia 
Lateral malleolus Medial malleolus 
Tibia Fracture created 
Figure 10: Showing position of tibia fracture in relation to fibula, taken from mouse 
genome Informatics, www. informatics. jax. org/ cookbook/figures /figure43.shtml 196 
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Minimal force was then applied to the lever as it was lowered onto the leg until a 
fracture was both heard and felt. The fracture was then immobilised by careful 
application of an above knee plaster cast. The cast was extended, proximal as 
possible, on the femur to ensure that it remained in situ and was not removed. The 
foot was placed in 90 degrees of dorsiflexion. 
Anteroposterior (AP) and lateral orientated radiographs of the fractured limb were 
then taken under General Anaesthesia. Carefully the mouse was returned to a 
thermostatically warmed recovery cage and placed in the lateral recumbency position 
and allowed to recover from the anaesthesia. The mouse was monitored constantly 
until it was fully conscious and then hourly for the next four hours. 
6.3.8 IMMEDIATE POST FRACTURE CARE AND MONITORING 
Post operatively pain and body temperature were monitored carefully. Pain was 
assessed by posture, fur (piloerection), behaviour, mobility, eating, drinking and 
bodyweight. Four factors of behaviour were recorded on table XI (Appendix 1) and 
each was marked out of a total of 2; 0 for normal, 1 for mildly abnormal and 2 for 
grossly abnormal. A maximum score of 8 was deemed unsatisfactory i.e. all 4 
domains were grossly abnormal. This chart had been previously used in our unit. If 
there appeared to be any signs of pain buprenorphine was given subcutaneously, 8 
hourly as required. 
The mice were at particular risk of hypothermia due to their small size so body 
temperature was maintained by a number of measures: An injection of subcutaneous 
warmed saline was used before the fracture was created. Post fracture a thermostatic 
heat matt was placed below the recovery cage and tissue was placed within the cage 
to keep the mice warm. The cages were also kept in a general warm environment. 
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To allow ease of feeding post fracture, food was moistened, mushed up and place in 
petri dishes on the cage floor. Drinking was also made easier with longer sipper 
drinking tubes. 
The weight bearing status of the fractured limb in plaster was also recorded 
( Normal, Placing foot, Lifting foot, Dragging foot). The aim was to see a return to 
normal weight bearing on the fractured limb by 24 hours post procedure. 
6.3.9 CONTINUOUS LONG TERM MONITORING 
Daily clinical signs from chart 2 were measured and recorded on each mouse in the 3 
groups until they were killed on days 7,14 or 21 post fracture. A mouse who had an 
overall appearance and behavioural score of 6 or below and had loss more than 20% 
of their body weight was discussed with the Edinburgh University Veterinary Service 
(EVS). We had no mice in this category. An animal underwent schedule 1 euthanasia 




The materials used in the radiographic protocol were the Acu -ray x -ray machine 
(Sterne Medical, Ontario, Canada) and Agfa TM radiographic film paper( Agfa- 
Gevaert, Mortsel, Belgium). The radiographic protocol is subsequently described. 
Agfa X -ray film was loaded into film cassettes in the dark room. The cassettes were 
placed on the wooden boxes and the anaesthetised mouse placed on this as set up in 
figure 11. The Acu -ray X -ray machine was turned on and set to an exposure time of 
0.06 seconds and voltage of 60kV. A jig was used to control rotation and 
magnification. These settings had been previously used in earlier studies in our unit. 
The fractured tibia was centred in the x ray beam by using the light collimator. A 
metal label was placed within the area of exposure to identify the individual mouse. 
Radiographs were then taken in the lateral and anteroposterior position. To 
standardise the AP x -ray for all the individual mice 2 small sized sponges were 
placed on either side of the tibia whilst the x -ray was taken. The anaesthetised mouse 
was then carefully returned to the warm cage to recover from the procedure. 
Figure 11: X -ray set up with fractured tibia 










6.3.11 RADIOGRAPHIC DEVELOPING 
The x -ray developer was turned on and used when the machine had warmed up. The 
x- ray cassettes containing the exposed x -ray film were placed in the holding bay of 
the developer. In the dark the exposed film was carefully removed from the cassette 
and placed into the developer. The film was automatically passed through the 
developer and collected on the tray after processing. Each radiograph was then 
allowed to dry before further identification of the mouse and day from fracture was 
written on the films. 
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6.4 OUTCOME ANALYSIS OF FRACTURED MURINE TIBIA 
6.4.1 RADIOGRAPHIC EVIDENCE OF CALLUS FORMATION 
To identify the amount of callus formation between the the depleted CD8 +, CD4+ T 
lymphocyte and control groups at days 7,14 and 21 post fracture the following 
protocol was used. There was no blinding of the examiner to the x -rays or image 
analysis. 
AP and lateral radiographs of the fractured tibia that had been taken on days 7,14 and 
21 were used. Initially, the radiographs were directly digitally scanned to a laptop 
computer. However, because the radiographs were relatively dark, the scanner was 
unable to re- produce these radiographs digitally. This method was therefore 
abandoned. Instead digital images were created using a light box and Canon 30D 
digital SLR mounted on a tripod. The focal distance was set at 30 cm and the camera 
settings were kept as standard for all images allowing magnification to be controlled 
(ISO 250, Shutter speed 1/125 sec, Aperture f22, manual focus). All the images were 
saved as JPEG digital images. 
ImageJ software (National Institutes of Health, USA, Version 1.43) was used for 
image analysis of the digital radiographs. Each radiograph both AP and lateral was 
imported to the software. Initially the image was white balanced using the stainless 
steel label identifier as a standard reference. Then the image was zoomed in to 70% 
over the fracture tibia site. Using the software measurer the callus and fracture 
margins were identified and then marked. From this the area of the callus was 
measured in pixels. The AP and lateral areas were recorded for each fractured limb in 
the 3 groups on days 7, 14 and 21 post fracture. This method of image analysis had 
previously been used in our unit. 
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6.4.2 RADIOGRAPHIC MEAN CALLUS: FEMORAL SHAFT PIXEL 
DENSITY RATIO 
To identify any difference in callus density in each group the mean callus: femur 
shaft pixel density ratio was measured. Each lateral radiograph from each mouse in 
each of the 3 groups was uploaded to ImageJ software (National Institutes of Health, 
USA, Version 1.43) and white balanced as previously described. Using the femur 
from the fractured side, 3 squares measuring 2mm x 2mm were placed at 3 set points 
along the femur, and the mean femoral shaft pixel density was recorded. Then the 
edge of the tibial fracture callus was identified, the pixel density within this 
measured three times and the average taken. The ratio of mean callus to mean 
femoral shaft pixel density was then calculated in the control, depleted CD4+ and 
depleted CD8+ groups. 
This ratio did not account for the variability in thickness of the callus. To overcome 
this a derivation of the Beer- Lambert Law was used to measure the callus density by 
including the thickness of the callus. 
The Beer Lambert law correlates the transmission of light T through a substance and 
the product of the absorption coefficient alpha, a, and the distance L, figure 12 197. 
L 
Figure 12: Diagram of Beer -Lambert demonstrating absorption of light through 
fracture callus of thickness edited from http: / /teaching.shu.ac.uk/hwb /chemistry/tutorials/ 
molspec/beersl.htm 197 
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Transmission T= I/ Io 197 
From our radiographs, Io was taken as background pixel density measured from an 
area adjacent to the bone and I, the callus pixel density 
Absorbance A = Logio (Io/I) 197 
A= Log 10 ( Background Pixel Density /Callus Pixel Density) 
Using the Beer- Lambert law for Absorption 
A= ecl 197 
where e = the molar absorptivity of calcium, c= the density of the fracture callus 
(mm3) , 1= fracture callus thickness (mm). `e c'were taken as a constant in bone 
Combining both equations 
A = Logic) Background Pixel density =ecL 
Callus Pixel Density 
(Logio Background Pixel density/ Callus Pixel Density)= ecL 
Therefore, if ̀ e' is taken as a constant 
c= (Log to Background Pixel density / Pixel callus)) 
L 
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6.4.3 LIMB DISSECTION 
At the time of dissection, both hips were initially disarticulated and the skin removed 
from the limbs. Each leg was then cut through the knee and ankle, leaving the tibia 
intact and any callus undisturbed. Tibia removed at day 7 and 14 post fracture were 
decalcified prior to histological and immunochemical testing. Tibia taken at day 21 
post fracture were placed into PBS prior to four point mechanical testing. 
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6.4.4 MECHANICAL FOUR POINT BENDING 
Mechanical four point bending was used to measure the yield point in each group of 
the fractured tibia at day 21 post fracture. This technique had been standardised in 
previous experiments in our unit and involved the subsequent materials; 
Zwick /Roell Z005 testing machine (Zwick GmbH & Co, Ulm, Germany) 
Programme: testXpert version 9.01 
Computer: Dell, Pentium II Processor 
A custom made four point loading device (use in previous studies in our unit, see 
Figure 11) 
A pair of Callipers 
The protocol for the mechanical four point testing is subsequently described. 
Before the tibia was tested, the extrinsic properties of the fracture callus were 
measured. These consisted of the diameter (mediolateral) and vertical height 
(anteroposterior) of the callus at the fracture site using the calliper. The measurement 
was repeated three times and the average taken. 
The apparatus was set up as in figure 13. Before the bone was mechanically tested a 
matchstick was placed in the machine. This was to test all the mechanical 
components were aligned so that only 4 point bending would be tested rather than 3 
point, figure 14. 
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Figure 13: The apparatus set up for 4 point bending 
Figure 14: The apparatus set up for 4 point bending 
Pivot 
4 Point load application 
Matchstick /Bone 
4 Point bending support 
Pivot 
4 Point load application 
Matchstick /Bone 
4 Point bending support 
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The fractured limb was place onto the 4 point bending support of the Zwick machine. 
The limb was orientated so that the fracture callus was centred with the tibial 
tuberosity, on the anterior border of the tibia, facing the ceiling. This orientation was 
kept constant for each tibia. The Zwick machine ends were then lowered so they 
were just above the limb, Figure 15, and the settings made (Grip 1051, Length 
100mm/min, Speed of deformation 2 mm/min, Upper Force 500 N). Four point 
bending of the fracture callus was then carried out. The test was completed to failure 
of the callus, Figure 16. This was determined by an audible crack in association with 
a sharp fall on the force (N) / deformation (mm) graph (TestXpertTM). The test was 
then repeated using the left unfractured tibia in the same mouse, and then amongst 
the different groups- CD4+ depleted, CD8+ depleted and control. 
The 4 point load application is 
lowered so that it just touching 
matchstick/bone 
Figure 15: The lowering of the 4 point application to the matchstick or tibia 
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4 point bending 
of failure of a 
is when a crack would 
heard in the tibia and 
would cease. 
Figure 16: Demonstrating the failure of a matchstick or tibia using the 4 point bending 
apparatus 
r 
6.4.5 THE EXPRESSION OF BIOMECHANICS RESULTS FROM FOUR 
POINT BENDING 
The data obtained from the Zwick four point bending machine was expressed in 
force (N) by displacement graphs by testXpert TM. The load at yield and failure were 
taken directly from the force (N) /displacement (mm) graphs. The point of yield was 
defined as the point on the graph where the load/ deformation curve became 
nonlinear. 
Using the following equations and assumptions the intrinsic properties of the 
fractured callus in each group were then calculated as follows. 
The fracture plain was considered to be an ellipse. Using the measurements of 
diameter and vertical height of the callus the area of the fracture ellipse was 
calculated 
The area of the ellipse= Width x {Ix Height 
4 
The Euler- B beam bending theory was used to measure the bending stress 198,199. 
The stress was then calculated using the cross sectional moment of inertia of an 
ellipse (I) as this was the given amount of material around a given axis. 
I = 1/4 x rj x ( vertical radius)x(horizontal radius) 3 
The vertical radius was taken as half the anteroposterior measurement and the 
horizontal radius was taken as half the mediolateral height. 
This measurement I was then used to calculate the bending stress, figure 17. 
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Distance from 




Figure 17: Diagram of measurements used from 4 point bending to calculate bending 
stress where F = Force, d= displacement, a= distance from outer to inner contact and 1= 
length. 
Bending Stress of tibia = F x x c 
2I 
where c= the half the vertical diameter of the tibia when positioned within the j ig and 
a= the distance from the outer to inner contact, (constant at 2mm) 
198 
The strain was then calculated using the formula, 
Strain = 6x vertical radius x displacement 198 
,(3L -4.,) 
Length between the two outer fulcra (L) = was kept at constant, 12mm 
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The Young's modulus was then calculated by using the formula, 





Before histology could be performed the tibia had to be decalcified and then mounted 
onto slides, which will now be described. 
6.4.6.1 DECALCIFICATION OF BONE 
The materials prepared were 10g of Sodium EDTA and 80 mis of distilled water. The 
EDTA was dissolved at pH9.0 and reduce down to pH 7.0 before adding 10 mis of 
40% formaldehyde. This was then made up to a total of 100 mis with distilled water. 
Dissected tibia were placed into sterile tubes containing 10 mis of 10% EDTA at pH 
7.0. This solution was replaced every third day with fresh solution and the tibia tested 
for hardness and flexibility by compressing the tibia between the index finger and 
thumb. When the tibia was able to able to be bent into a u shape with minimal force 
so lacking rigidity they were placed into 50% ethanol ready for histological, 
immunological and stereology testing. 
6.4.6.2 MOUNTING THE TIBIA IN PARAFFIN AND SECTIONING 
The tibia at day 7, 14 and 21 post fracture were mounted onto paraffin blocks. 
Paraffin block were then placed on the microtome and cut into 31.1.m samples. The 
first 20 layers were discarded and then layer 21 was placed in water and mounted 
onto a slide. This was reviewed under a light microscope to identify if the fracture 
callus was present. A further 20 cuts were made and the second layer was then 
reviewed under the light microscope. This was repeated until the callus layer was 
reached. This was then sectioned into 3µm thick slices and mounted on 
SuperFrostTM slides ( BDH, Poole, UK). The slides were then incubated at 37 °C 
overnight, then stored in the dark at 37 °C. 
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The following histological and immunological tests were then applied to the 3µm 
sectioned fractured tibia callus in each of the 3 groups, depleted CD4 T lymphocytes, 
depleted CD8 T lymphocytes and control. 
6.4.6.3 HAEMATOXYLIN AND EOSIN (H &E) STAINING 
A H &E standard protocol was used to identify the general structure of the fracture 
(Appendix 2) 
6.4.6.4 TOLUENE BLUE STAINING 
A standard protocol Toluene Blue protocol was performed to identify cartilage within 
the callus formation of the tibia fracture for Stereology, (Appendix 2). 
HE and Toulon blue slides of the callus were visualised and imaged using a Zeiss 
Axiovision camera and Zeiss upright microscope (Carl Zeiss, Ltd Uk). Zeiss 
microAxiovision 4.8.1.911 -2009 software (Carl Zeiss, Ltd Uk) was used to create 




The following equipment was used to determine the amount of callus formation in 
the depleted CD4 T lymphocytes, depleted CD8 T lymphocytes and the control 
groups at day 21 post fracture. 
Camera - Qlcam ( Qlmaging, Canada) 
Microscope- Zeiss Axio Imager Al, (Carl Zeiss Ltd, United Kingdom) - lens x 2.5 
and x20 
Prior Pro automatic stage( Prior Scientific Instruments Ltd, Cambridge, UK) 
Viewsonic screen 
Software: Image -Pro Plus TM ( MediaCybernetics Inc, USA) 
Slides used: Murine tibia fractures CD8+ depleted, CD4+ depleted and control at day 
21 [post fracture Stained with Toluene Blue to identify Cartilage- blue and bone - 
purple 
The following stereology protocol had been established in the laboratory to identify 
the volume of sertoli cells in testis but it was adapted to measure the mean 
percentage of callus and bone within each callus sample 200,201 
The callus on the slide was identified using the x2.5 lens. The lens was changed to 
the x20 and the camera icon was opened on the menu bar on the computer. The 
image obtained on the computer was then white balanced. The lens was then changed 
back to x2.5. The tiling setting was set to `tile by slide' and to a tiling objective of 
x002.5. 
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A tile was then applied to the image by firstly selecting the `tile' label. A small box 
then appeared on the screen and this was moved to the far left of the boundary of the 
tibia specimen and clicked. This was repeated to confirm the right, top and bottom 
boundaries of the specimen. An area out of the specimen was then selected and 
clicked, which created the image into tiles on the screen. 
To measure the fracture callus area, the area of interest, had then to be identified. 
This was achieved by firstly selecting `Add' from the menu bar. Arrows then 
appeared which were moved with the computer mouse to identify the boundary of 
the fracture callus. Completion of the boundary was confirmed by clicking the mouse 
which changed the line from red to green figure 18. 
Tibia 
Fracture Callus 
Boundary of area of 
fracture callus 
E-- Tibia 
Figure 18: Illustration of the boundary of the fracture callus. This was identified by 
recognising the edge of the fracture bone ends and the callus between them using the 
x2.5 lens. The fracture callus boundary was then marked by drawing a green line . 
The number of fields within the area of interest had then to be identified. The `Points' 
icon was then selected from the experimental layout information bar. The Centre/ 
experiment object size was highlighted and 25 was entered into the random points 
bar. The random points bar was the number of fields that were counted on each slide. 
This number was calculated to create a less than 5% standard error of data.There was 
no blinding of the examiner to the slides used in the Stereology. 
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The 25 random point squares were then generated over the callus area by selecting 
`Go'. Before proceeding the majority of the point squares were ensured to be over 
the callus area rather than the boundary, figure 19. 
Figure 19: the 25 visual fields in place around the callus (x2.5 magnification) 
If there was any concern with the placement of these squares then another 25 random 
square fields were generated. The following settings were applied before the 
experiment was commenced; the experiment objective was x20, thickness = 101.tm, 
probe port = 3, Grid offset = 10x10, grid size = 14x13, count frame = 320x320. Once 
the experiment had begun each of the 25 random point visual field squares appeared 
consecutively on the screen. Each square was focused and the light source altered as 
required. The square was ignored and not counted if there was less than 50 % of 
callus within the square image. Choosing 25 random points allowed for a minimum 
of 15 visual field squares to be counted with 10 squares ignored. 
Within each visual field square the amount of cartilage, bone and other tissue was 
measured. This was achieved by selecting `focus' from the menu bar which created a 
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green grid over the visual field, figure 20. The areas of the cartilage were then 
measured by selecting those crosses which overlay the cartilage, figure 21. 
Figure 20: computer screen at x20 visual field demonstrating grid 
Figure 21: selected crosses over cartilage areas in visual field at x20 
Crosses that were on the edge of the cartilage were not counted. The same set of 
squares was then used to count the areas of bone and other material in the callus. 
This technique was then repeated for a minimum of 15 visual fields for each slide. A 
minimum of 3 slides from the same murine model were used in each of the 3 groups, 
CD4+ depleted, CD8+ depleted and control. 
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6.4.7.1 CALCULATING THE PERCENTAGE OF CARTILAGE AND BONE 
To work out the percentage of cartilage and bone in each slide firstly the total 
possible number of points per slide was calculated, 
Total possible number of points per count= number of points per grid x number of 
visual fields measured 
e.g. Total possible number of points per count (P)= (14x13) x10 =1820 
Then the Total number of points was calculated per slide (S), 
(S)= P x number counts per slide 
Subsequently the percentage of callus/ bone was measured per slide (C), 
(C) = Sum of callus/ bone points x 100 
S 
Finally the mean_percentage of bone and callus per group was calculated, 
Mean % C -= Sum of C from each slide in the group 
Total Number of Slides in the group 
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6.4.8 SINGLE LABELLED IMMUNOHISTOCHEMISTRY 
The immunohistochemistry staining was performed on paraffin embedded mouse 
spleen as a standard protocol (see Appendix 2) using the following materials to 
identify leucocytes, and more specifically CD4+ and CD8+ T lymphocytes; 
Dako Envision TM and system HRP (K4004, Dako Ltd, UK) 
CD3 ANTIBODY: A rat monoclonal antibody (VP- C317) supplied from Vector 
Laboratories ( CA 94010, USA), with the ability to identify early thymocytes and 
native T cells. 
CD45R ANTIBODY: A purified rat anti -mouse antibody (B220) supplied from BD 
Pharmingen TM(Oxford, UK), with the ability to identify B Lymphocytes, T 
lymphocytes, Natural Killer cells. 
CD8 ANTIBODY: A mouse antihuman monoclonal antibody ( M7130) , supplied 
by DakoCytomation (Glostrup, Denmark) with the ability to identify CD8+ T 
Lymphocytes. 
CD4 ANTIBODY: A mouse antihuman monoclonal antibody (VP -C -319) supplied 
by Vector Laboratories ( CA 94010, USA), with the ability to identify CD4+ T 
lymphocytes. 
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6.4.9. DOUBLE LABELLED IMMUNOFLUORESCENCE 
Double immunofluorescence was used to identify initially CD4+ and CD8+ T 
lymphocytes and then CD4+ and CD3+ T Lymphocytes in paraffin embedded mouse 
spleen and then bone. The protocol varied with the antibody utilised. The common 
protocol is described below with detailed variations explained under separate 
subheadings. 
Embedded paraffin section of mice spleen were incubated in 60 degrees for 15 
minutes. They were then prepared by dewaxing in xylene for two, 5 minute washes 
and then submerged in reducing concentrations of ethanol (100 %, 70 %, 50 %) and 
then water for 1 minute. The slides were then transferred to a pressure cooker 
containing Borg Solution (MenaPath LOT 022009) ready for antigen retrieval. The 
slides were ensured to be submerged in the solution before they were heated in a 
microwave on full power for 2 minutes when the pressure had been reached. The 
slides were allowed to cool for 20 minutes before they were removed from the 
pressure cooker and washed in running water and then twice in PBS. The slides were 
then quenched with 3% hydrogen peroxide in methanol for 5 minutes at room 
temperature to block peroxidase, and then washed twice with PBS before loading the 
slides into sequenza coverplateTM clips and sequenzaTM slide racks (Thermo 
Shandon, Cheshire, UK)( point x). The sequenza coverplateTM system was used to 
reduce the volumes of antibody used and allow the equal distribution of 125111 of 
regent across the slide by capillary action. 
Once the slides were loaded into the sequenzaTM they were initially washed with PBS 
and then 3 drops (approximately 1251.1l) of Avidin Block ( SP -2001, Avidin/Biotin 
Blocking Kit, Vector Laboratories Inc, Burlingame, CA 94010) were added to each 
slide and incubated for 15 minutes at room temperature. The slides were then washed 
three times with PBS and then 3 drops of Biotin block (SP -2001, Avidin/Biotin 
Blocking Kit, Vector Laboratories Inc,USA) were added to each slide, and incubated 
for 15 minutes at room temperature. After additional washing with PBS IgG mouse 
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antibodies were blocked by adding 2 drops of stock solution of M.O.M.'M IgG 
Blocking regent (M.O.M.TMKit, BMK -2202, Vector Laboratories, USA) to each slide 
and incubating for an hour at room temperature. Following further washing with 
PBS, 125µL of working solution of M.O.M. Diluent (M.O.M.TMKit, BMK -2202, 
Vector Laboratories,USA) was added for 5 minutes to each slide at room 
temperature. 
1251.1L of specific primary antibody, diluted with M.O.M diluent to a concentration of 
1:100, was then added to each slide and incubated at room temperature for 1 hour. 
Following five washing with PBS 1251.IL of secondary fluorescent secondary 
antibody diluted to 1:100 in M.O.M diluent was added to the slides and incubated at 
room temperature for 30 minutes. The slides were then washed 5 times with PBS 
before 3 drops of MOM protein block were added to each slide and incubated for an 
hour at room temperature. 1251.IL of the second primary antibody diluted in M.O.M 
diluent (1:100) was then added to certain slides and incubated for an hour at room 
temperature. .All the slide were then washes with PBS 5 times. 1254 of the second 
fluorescent secondary antibody diluted in M.O.M diluent (1:100) was then added to 
certain slides and incubated for 30 mins at room temperature. All slides were 
subsequently washed with PBS and 1251.1L of DAPI at 1: 1000 dil in PBS was added 
to each slide and incubate for 10 mins at room temperature in the dark. Slides were 
again washed in PBS and mounted in mounted with Permafluor ®(Thermoscientific, 
Basingstoke, UK). In all the experiments the controls slides consisted of spleen 
samples with variations in absence of primary or secondary antibodies. 
The slides were observed under the confocal microscope (Leica TCS SP5, Leica 
Biosystems Ltd, Milton Keynes, UK) using an inverted microscope base 
(LeicaDMl 16000, Leica Biosystems Ltd), an environmental chamber to maintain 
optimal conditions for live cell imaging (temperature, humidity, carbon dioxide 
concentration and air humidity) and Leica Application Suite Advanced Fluorescence 
software (Leica Biosystems Ltd, Milton Keynes, UK). CD8+ and CD4+ T 
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lymphocytes were identified by contrasting different immunofluorescence dyes 
which is explained in more detail in each antibody specific section below. 
6.4.9.1 CD4 ANTIBODY 
Mouse CD4 antibody (CD4 Clone 4B12 ), a monoclonal antibody, was supplied by 
Vector Laboratories (CA 94010, USA). It had been found to identify the CD4 subunit 
present on T (helper /inducer) lymphocytes in mice. Positive binding was detected 
with the use of conjugated secondary antibody, goat anti -mouse Alexa Fluor® 488 
secondary (Invitrogen Ltd, Paisley, UK). 
Primary antibody was diluted to 1 in 100 with M.O.M TM Diluent (Vector 
laboratories, USA) and incubated in the sequenza overnight at 4 °C.. The secondary 
antibody was diluted 1 in 100 with M.O.M 'Diluent (Vector laboratories, USA) and 
incubated in the sequenza for 30 minutes, at room temperature in the dark. 
6.4.9.2 CD3 ANTIBODY 
Two CD3 primary antibodies were used for the double immunofluorescence 
experiments. The first primary antibody, (VP -C317) was used in all of the 
experiments using mouse spleen but this was changed to the second antibody (Sigma 
C7390) in the later experiments when formalin fixed and paraffin embedded mouse 
bone tissue was tested with mouse spleen. 
Rat CD3 antibody ( VP -C317) was supplied by Vector Laboratories (CA 94010, 
USA). It was found to identify early thymocytes and native T cells in rat, mouse, 
human, chicken, dog and horse. Positive binding was detected with the use of 
conjugated secondary antibody, goat anti -mouse Alexa Fluor® 633 (Invitrogen 
Ltd,Paisley,UK) initially then goat anti -mouse Alexa Fluor® 555 (Invitrogen 
Ltd,Paisley,UK). 
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Rabbit CD3 antibody (C7390) was supplied by Sigma- Aldrich Company Ltd 
(Dorset, UK). It was found to identify early thymocytes and native T cells in rabbit, 
mouse and human. Positive binding was detected with the use of conjugated 
secondary antibody, goat anti -mouse Alexa Fluor® 633 (Invitrogen Ltd,Paisley,UK) 
The CD3 antibody was diluted to 1 in 100 with M.O.M TM Diluent (Vector 
laboratories, USA) and incubated in the sequenza overnight at 4 °C. The secondary 
antibody was diluted 1 in 100 with M.O.M TM Diluent (Vector laboratories, USA) and 
incubated in the sequenza for 30 minutes, at room temperature in the dark. Used in 
combination with the CD8 antibody would allow identification of both CD8+ and 
CD4+ T lymphocytes. 
6.4.9.3 CD8 ANTIBODY 
The monoclonal mouse anti human -antibody (M7130) was obtained from 
DakoCytomation (Glostrup, Denmark). It has been shown to identify the majority of 
thymocytes and the class I major histocompatibility complex restricted to cytotoxic/ 
suppressor T lymphocytes. The conjugated secondary antibody used for detection 
was goat anti -mouse Alexa Fluor® 633 (Invitrogen Ltd,Paisley,UK). 
In the double immunofluorescence protocol the CD8 antibody was diluted to 1 in 100 
with M.O.M "Diluent (Vector laboratories, USA) and incubated in the sequenza 
overnight at 4 °C. The secondary antibody was diluted 1 in 100 with M.O.M 
TM 
Diluent (Vector laboratories, USA) and incubated in the sequenza for 30 minutes, at 
room temperature in the dark. 
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6.4.9.4 DOUBLE LABELLED IMMUNOFLUORESCENCE WITH 
TYRAMIDE 
The protocol for this was initially identical to the standard immunofluorescence 
described earlier, section 6.4.9, until after the slides were quenched with 3% 
hydrogen peroxide in methanol. The continued altered protocol is described here. 
Following quenching the slides were washed with PBS and blocked with 1254 of 
normal chicken serum (10% chicken serum : 10 % mouse serum in dako blocking 
agent (DAKO Ltd, UK) for 30 minutes at room temperature. The slides were drained, 
the excess wiped away and 1254 mouse primary antibody diluted in 10% mouse 
serum : chicken serum diluent was added to the slides which were incubated 
overnight in a dark room at 4 °C. The slides were then washed for 10 minutes with 
PBS containing 0.05% tween and then just PBS for 5 minutes. Goat anti mouse 
peroxidase fab diluted 1: 500 in 10% mouse: chicken serum diluent was then added 
to each slide for 30 minutes at room temperature. Again the slides were then washed 
with a combination of PBS with 0.05% tween and then PBS alone. Tyramide 
Cyanine 3( NEL 704A) diluted in 1:50 in substrate was then added to each slide for 
10 minutes at 20 °C. The slides were then washed with PBS containing 0.05% tween 
and then just PBS for 10 minutes. All the slides were then submerged in 400mls of 
0.01M citrate buffer and boiled for 2.5mins on full power in the microwave. The 
slides were then allow to cool for 30 minutes before 1254 of 10% mouse: chicken 
serum was added to the slides for 30 minutes at room temperature as a block. The 
slides were then drained, the excess wiped away and 1254 of the second primary 
mouse antibody diluted in 10% mouse: chicken serum added to each slide. The slides 
were left to incubated at 4 °C in the dark. The slides were then again washed in PBS 
containing 0.05% tween and then PBS alone. To amplify the detection of the 
antibody tyramide fluorescein diluted 1:50 in substrate was added to each slide for 10 
minutes at 20 °C. The slides were finally washed with PBS with 0.05% tween and 
then PBS alone for 5 minutes before they were counterstained with DAPI as 
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previously described. All controls in this experiment consisted of a variation in 
absence of primary or secondary antibodies. 
6.4.9.5 IMMUNOCYTOCHEMISTRY, DETECTION OF CD4+ AND CD8+ T 
LYMPHOCYTES 
Immunocytochemistry was used to identify whether the concentration of the primary 
antibody had an effect on the detection of the CD4+ and CD8+ T lymphocytes in 
paraffin embedded mouse spleen. The materials included the Dako EnvisionTM( Dako 
Ltd, UK) and system, HRP (DAB) with primary rabbit monoclonal antibodies; CD3 
(AB 5690, Abcam R,UK), CD8 (1872, Epitomics R, UK). These particularly 
antibodies were chosen as they had previously been used in the unit. The protocol for 
this was initially identical to the standard immunofluorescence described earlier, 
section 6.4.9, until after the slides were quenched with 3% hydrogen peroxide in 
methanol. The continued altered protocol is subsequently described. 
Following quenching the slides were washed with PBS and 125µL of CD3 or CD8 
antibody diluted with antibody diluent (Spring Bioscience, CA, USA) to a variety of 
concentrations (1:100, 1:250, 1:500 ) and added to each slide for an incubation time 
of r 30 minutes at 20oC. For 4 slides of 1:250 and 1:500 concentration incubation 
was continued overnight. The slides were then washed with PBS and 3 drops 
(approx. 125µL) of peroxidase labelled polymer- hrp anti rabbit (Dako Ltd, UK) 
were added to each slide and incubated for 30 minutes at 200C . The slides were 
washed in PBS and 1ml of DAB substrate buffer (Dako Ltd, UK) with 3 drops of 
DAB Chromogen (Dako lid, UK) were then added to each slide for 30 minutes at 
20 °C. Again the slides were washed with PBS before being counterstained. This was 
achieved by 30 seconds in haematoxylin, 5 seconds in acid alcohol and then 1 minute 
in Scott's tap water with PBS washes in between these steps. The slides were then 
mounted with pertex. The controls in this experiment were spleen samples with 
absent CD3 or CD8 primary antibodies. 
115 
6.4.9.6 IDENTIFYING CD8+ AND CD3+ T LYMPHOCYTES IN SPLEEN 
PRESERVED WITH DIFFERENT FIXATIVE SOLUTIONS 
Immunocytochemistry was used to identify whether the fixation solution, either 
formaldehyde or methacarn had an effect on the detection of CD8+ and CD3+ T 
lymphocytes in paraffin embedded mouse spleen, mouse tonsil tissue was used as a 
control. The same rabbit antibodies CD3 and CD8 were used with the DAKO 
envision kit and HRP(DAB) as previous described, Section 6.4.9.5. Two of the four 
spleen sections used had been preserved in formaldehyde and two had been 
preserved in methacarn. The protocol used was identical to section 6.4.9.5 although 




7.0 IN VIVO RESULTS 
7.1 RESULTS OF DEPLETION OF CD4+ AND CD8+ T 
LYMPHOCYTES 
The aim of this experiment was to deplete CD4+ and CD8+ T lymphocytes in the 
murine model by day 16 using the method previously described in section 6.1.1. 
Confirmation of depletion of the CD4+ and CD8+ T lymphocytes was made using 
FACS. The FACS figures 22 -24 subsequently showed the successful depletion of 
CD4+ and CD8+ T lymphocytes compared to controls. The axis illustrate the number 
of lymphocytes detected by the FACSCalibur machine ( Becton Dickson, San Jose, 
USA). The CD4+ and CD8+ T lymphocytes groups can be identified as 2 distinct 
populations as they had different fluorescent isotopes attached to them (PE or FITC). 
When passing through the FACS argon laser these isotopes are excited and emit 
photons. The photons emitted from the FITC isotope have a different wavelength to 
PE. Therefore the FACS sensor can detect 2 distinct wavelengths. The amount of 
fluorescent photon signal detected is proportional to the number of fluorochrome 
molecules on the particle 202 which the computer interprets into 2 distinct groups, 
CD4+ or CD8 +lymphocytes. 
The depleted CD4+ group had 0.6% of the CD4+ T lymphocytes (figure 23) 
compared to 22.55% in the the control group, figure 22. The depleted CD8+ group 
showed that only 0.10% of CD8+ T lymphocytes were identified compared to 
12.75% in the control group, figure 24. 
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Figure 22 Identification of CD4+ and CD8+ T lymphocytes in a single Control Mouse 
Spleen at day 16 using FACS. The 2 distinct groups of CD4+ T lymphocytes and CD8+ T 
lymphocytes are identified by arrows. 
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Figure 23 Depletion of CD4+ T Lymphocytes in a single CD4+ Depleted Mouse spleen 
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Figure 24 Depletion of CD8+ T Lymphocytes in a single CD8 Depleted Mouse spleen 
at day 16 using FACS. The graphs shows 0.10 % of CD8+ T lymphocytes detected. 
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The overall depletion experiment of CD4+ and CD8+ T lymphocytes with n =5 in 
each group is illustrated below, Figure 25. 
The Percentage Mean of CD4+ and CD8+ T Lymphocytes 
Identified In The Depleted Lymphocyte Groups At Day 16 






Mouse Depletion Groups 
Figure 25 The mean percentage of depletion of CD4+ and CD8+ T lymphocytes 
compared to control at day 16. The number in each group was 5. The error bars denote 
standard error of the mean. Statistical analysis using Student t test, compared to controls, 
CD4+ depleted *p <0.005, CD8+ depleted * *p <0.005 
Both CD4+ and CD8+ T lymphocytes had reduction in mean percentages in their 
depleted groups. For the CD4+ depleted group the mean percentage identified was 
1.1% compared to 17.8 % in the control group (p= 0.0046, 95% CI 9.786 to 23.714) 
i.e. the level was 6.2 % of that in the controls. In the CD8+ depleted group the mean 
percentage identified was 0.2% compared to 10.22% in controls (p= 0.0027, 95% CI 
95% CI 6.563 to 13.518) i.e. the level was 1.9% of that in the control. 
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7.2. RESULTS OF DEPLETION OF CD4+ and CD8+ T 
LYMPHOCYTES POST FRACTURE 
The aim of this experiment was to confirm that depletion of CD4+ and CD8+ T 
lymphocytes remained after the fracture in the tibia was created. 
7.2.1 CD4+ T LYMPHOCYTE DEPLETION 
Figure 26 and table VI below illustrate the depletion of the CD4+ T lymphocytes 
over the experimental 21 days. 
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Figure 26: The percentage depletion of CD4+ T lymphocytes compared to controls at 
days 7, 14 and 21 days post fracture. Table VI: The actual percentage of CD4+ T 
Lymphocytes detected in the CD4+ depleted group and control at days 7, 14 and 21 
days post fracture. The number in each group day 7 n =4, day 14 n =4 and day 21 n =7. 
Error bars denote standard error of the mean. Statistical analysis using Student t test, 
compared to controls *p <0.001 
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The figure above illustrate that there is an overall 60% reduction in CD4+ T 
lymphocytes levels in the depleted group compared to the control. The depletion of 
CD4+ T lymphocytes was also maintained until day 21. Overall this study showed 
the depletion of CD4+ T lymphocytes was significant at each time point in the CD4+ 
depleted group compared to control, table VI. 
7.2.2 CD8+ T LYMPHOCYTE DEPLETION 
Figure 27 and Table VII below illustrate the depletion of the CD8+ T lymphocytes 
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Figure 27: The percentage depletion of CD8+ T lymphocytes compared to controls at 
days 7, 14 and 21 days post fracture Table VII: The actual percentage of CD8+ T 
Lymphocytes detected in the CD8+ depleted group and control at days 7, 14 and 21 
days post fracture. The number in each group day 7 n =4, day 14 n =4 and day 21 n =7. 
Error bars denote standard error of the mean. Statistical analysis Student t test, compared to 
controls * p <0.005 
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The above figure showed there was a general 65% reduction in CD8+ T lymphocytes 
levels in the CD8+ depleted group compared to the control. The depletion of CD8+ T 
lymphocytes was also maintained until day 21. Overall this study showed the 
depletion of CD8+ T lymphocytes was significant at each time point in the CD8+ 
depleted group compared to control, table VII. 
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7.3 OUTCOMES OF MURINE FRACTURE HEALING 
7.3.1 RADIOGRAPHIC EVIDENCE OF FRACTURES AND CALLUS 
FORMATION 
Figures 28 and 29 below are two examples of the anteroposterior and lateral 
radiographs taken at the time of fracture in the control group, day O. 
Figure 28: Anteroposterior radiograph showing 
the fractured tibia highlighted by the arrow 
Figure 29: Lateral radiograph 
showing the fractured tibia 
highlighted by the arrow 
Figure 30: Anteroposterior radiograph demonstrating callus formation at day 14 in 
control, highlighted by the arrow. 
The radiograph above, figure 30, taken at day 14 post fracture demonstrated the 
callus formation which was measured as previously described in section 6.4.1 using 
Image J software. The radiographic analysis of the mean callus formation obtained 
from each group at 7, 14 and 21 days post fracture will subsequently be described. 
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7.3.2 RADIOGRAPHIC ANALYSIS OF MEAN CALLUS SIZE OF 
FRACTURES 
Radiographic analysis of the callus formation is summarised in figure 31, and 
described below. There was no blinding of the examiner to the x rays identity. 
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Figure 31: Radiographic analysis of the mean callus size in each of the fractured 
murine tibia groups over 7, 14 and 21 days from fracture. The number in each group Day 
7 n= 15, day 14 n =11, day 21 n =7. Error bars denote standard error of the mean. Statistical 
analysis using One way ANOVA * * *p <0.001 CD4+ Depleted compared to Control,*+*p<0.001 
CD8+ Depleted compared to Control, ** p <0.01 CD4+ Depleted compared to CD8+ depleted, 
**p<0.005 CD8+ Depleted compared to Control, ^p<0.05 CD8+ Depleted compared to CD4+ 
Depleted by parametric tests. 
The mean callus size in the control group increased sharply from day 7 (297pixels) to 
day 14 (1766 pixels) and then gradually increased from day 14 to day 21 ( 3290 
pixels). The CD4+ depleted group demonstrated a sharp increase in callus size from 
day 7 (572 pixels) to day 14 (3810 pixels). However, this increase plateaued and 
there was no significant change between day 14 bad day 21. The CD8+ depleted 
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group a showed an increase in mean callus size from day 7 (530 pixels) to day 14 
(2092 pixels) and then a gradual increase from day 14 to day 21 (4874 pixels). 
Comparison between the 3 groups at day 7 showed there were significant differences 
in mean callus size between the depleted CD4+ and CD8+ T lymphocyte groups 
compared to control, with more callus in both depleted T lymphocyte groups (CD4+ 
depleted to control p <0.001 95% CI 156 -391, CD8+ depleted to control p <0.001 
95% CI 115 -350). At day 14 the CD4+ depleted T lymphocyte group had 
significantly more callus compared to both control (p <0.001 95% CI 738 -3379) and 
the depleted CD8+ T lymphocyte group (p <0.01 95% CI 412 -3023). At day 21 
however, the depleted CD8+ T lymphocyte group had significantly more mean callus 
compared to both control (p <0.005 95% CI 492 -2675) and the CD4+ depleted group 
(p <0.05 95 %CI 34- 2216). 
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7.3.3 MEAN CALLUS: FEMORAL SHAFT PIXEL BONE DENSITY RATIO 
The graphs below illustrate the mean pixel bone density ratio in the callus of the 
depleted CD4+ and depleted CD8+ T Lymphocytes compared to controls at day 14 
















Mean Callus: Femoral Shaft Pixel Density 
Ratio Day 14 Post Tibia Fracture 
Control CD4 Depleted 
Mouse Group 
CD8 Depleted 
Figure 32: Radiographic analysis of the mean callus: femoral shaft pixel density ratio 
in each of the murine groups day 14 post fracture. The number in each group n =7. Error 
bars denote standard error of the mean. Statistical analysis with one way Anova and post 
hoc Bonferroni, p <0.05 
The Mean Callus : Femoral Shaft Pixel Density Ratio 
Day 21 Post Tibia Fracture 
Control CD4 Depleted CD8 Depleted 
Mouse Group 
Figure 33: Radiographic analysis of the mean callus: femoral pixel density ratio in 
each of the murine tibia groups at day 21 post fracture. The number in depleted CD4+ 
and CD8+ T lymphocytes groups n =5, Control n =4. Error bars denote standard error of the 
mean. Statistical analysis with one way Anova and post hoc Bonferroní, p <0.05 
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The mean callus femoral pixel bone density ratios at day 14 and day 21 showed a 
trend of the CD8+ depleted group having the lowest mean callus to femur pixel bone 
density. However the differences in values between the 3 groups was not statistically 
significant either at day 14 or day 21. 
7.3.4 MEAN DENSITY OF FRACTURE CALLUS 
The graph, figure 34, below illustrates the mean density in the fracture callus at day 
21 in the depleted CD4 +, depleted CD8+ and control groups using the adapted Beer 
Lambert equation. 
Mean Density of Fracture Callus Day 21 Post 
Tibia Fracture 
CONTROL CD4 Depleted 
Mouse Group 
CD8 Depleted 
Figure 34: Mean density of fracture callus at day 21 post fracture in each murine 
group. The number in each group n =5. Error bars denote standard error of the mean, 
Statistical analysis with one way Anova and post hoc Bonferroni p <Q05. 
The graph above showed the CD4+ depleted group to have a greater mean callus 
density compared to the CD8+ depleted group but a lower value compared to 
controls. The CD8+ depleted group had the lowest mean callus density of all 3 
groups. All the differences in mean callus density between the groups were not 
statistically significant. 
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7.3.5 FOUR POINT BENDING MECHANICS 
The aim of this experiment was to quantify the properties of the fracture callus 
(displacement, radii, ultimate stress, ultimate strain, Young's modulus) in the CD4+ 
and CD8+ depleted T lymphocyte groups compared to control at day 21. The original 
data is presented in appendix B. Anomalous outlying results which demonstrated 
atypical results were excluded. (It was subsequently realised that fibula was healed or 
intact in some specimens.) The results were normalised, by comparing the results 
from the fractured tibia to the opposite unfractured tibia. The data shown in the table 
VIII below are the mean values which have been normalised. Statistical analysis was 
performed with one way Anova and post host Bonferroni testing, p was significant at 
0.05. 








CD4 1.2 1.485 2.87 3.31 9.7 
DEPLETED +/ -0.27 +/ -0.31 +1 -0.44 +/ -0.53 +/ -2.3 
CD8 0.6 2.106 2.89 3.28 9.4 
DEPLETED +/ -0.09 +/ -0.35 +/ -0.14 +/ -0.55 +/ -2.1 
CONTROL 1.1 1.783 3.68 1.57 5.7 










CD4 82.68 0.04 5.44 0.0085 
DEPLETED +/ -6.7 +/ -0.016 +/ -2.56 +/- 0.0002 
CD8 73.41 0.02 6.70 0.0040 
DEPLETED +/ -6.7 +/ -0.006 +/ -1.48 +/- 0.0003 
CONTROL 69.19 0.02 2.72 0.0093 
+/ -14.3 + / -0.008 +/ -0.99 +/- 0.0007 
Table VIII: The adjusted and normalised mean mechanical values obtained from four 
point bending of tibia fracture callus in CD4+ depleted, CD8+ depleted and control 
groups at day 21 post fracture. Numbers in each group, n =5 in CD4+ depleted and CD8+ 
depleted groups, n= 4 in control group. Standard error of the mean included for all values_ 
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Adjusted and Normalised Percentage of 














Figure 35: Adjusted and normalised percentage of yield point of murine tibia day 21 
post fracture. Numbers in each group, n =5 in CD4+ depleted and CD8+ depleted groups, 










Adjusted and Normalised Percentage of 
Stress of Murine Tibia Day 21 Post 
Fracture 
Control CD4 Depleted 
Mouse Group 
CD8 Depleted 
Figure 36: Adjusted and normalised percentage of failure stress of murine tibia day 21 
post fracture. Numbers in each group, n =5 in CD4+ depleted and CD8+ depleted groups, 
n= 4 in control groups. Statistical analysis with one way Anova and post hoc Bonferroni, 
p <0.05. 
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Adjusted and Normalised Percentage of 








Control CD4 Depleted 
Mouse Group 
CD8 Depleted 
Figure 37: Adjusted and normalised percentage of failure strain of murine tibia day 21 
post fracture. Numbers in each group, n =5 in CD4+ depleted and CD8+ depleted groups, 









Adjusted and Normalised Percentage of 
Young's Modulus of Murine Tibia Day 21 
Post Fracture 
Control CD4 Depleted 
Mouse Group 
CD8 Depleted 
Figure 38: Adjusted and normalised percentage of Young's Modulus of murine tibia 
day 21 post fracture. Numbers in each group, n =5 in CD4+ depleted and CD8+ depleted 
groups, n= 4 in control groups. Statistical analysis with one way Anova and post hoc 
Bonferroni, p <0.05 
Although no significance was detected amongst the groups the results do show a 
trend in the CD8+ Depleted group. The CD8+ depleted group had half the yield 
point, and Young's Modulus percentages than both the CD4+ depleted and control 
groups, (Figures 35, 38). Whilst the stress at failure was double that of the control 
group, (Figure 36). 
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7.3.6 HISTOLOGY 
Images below were captured on the Zeiss Axioskop microscope ( Carl Zeiss Ltd,UK) 
using QCapture Pro software version 6( Qlmaging Ltd, Surrey, Canada). 
Figure 39: Representative HE stained Histological images of fracture callus in Control 
(A) versus CD8 Depleted (B) and CD4 Depleted (C) at day 21 post fracture 
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Figure 41: Representative Toluene Blue Stained Histological Images X20 magnification 
of fracture callus in Control (A) versus CD8 Depleted (B) and CD4 Depleted (C) at day 21 
post fracture. The dark purple area indicates cartilage (CA) compared to bone ( BO) in blue. 
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Figure 40: Representative Toluene blue staining of the fracture callus in Control (A) 
versus CD8 depleted (B) and CD4 Depleted (C) at day 21 post fracture. 
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7.3.7 STEREOLOGY 
Histology sections stained with Toluene Blue were assessed using the stereological 
technique described in section 6.4.7 and the selective amounts of cartilage and bone 
were quantified in each fracture callus, for which the results follows. 
The aim of this study was to identify and quantify the mean percentage of cartilage 
and bone in each fractured callus, from each of the 3 groups, at day 21 post fracture. 
The mean percentage of cartilage and bone in the fractured callus are summarised in 
the figure 42. 
Mean Percentage Of Cartilage And 
Bone In Callus At Day 21 Post Fracture 




Figure 42: Fracture Callus composition in response to presence and absence 
of CD8+ and CD4+ T Lymphocytes. All data n= 7. Error bars denote standard error of the 
mean. Statistical analysis Ap <0.05 ( CD8 depleted cartilage vs Control), * *p <0.005 ( CD8 
depleted cartilage vs CD4 depleted), * * *p <0.001 (CD4 depleted bone vs CD8* depleted, Cd8 
depleted bone vs CD4 depleted and control by one way ANOVA test. 
Each group had an greater mean percentage of bone than cartilage in the callus at day 
21. Both the CD4+ depleted and control groups had similar proportions of bone to 
cartilage in their callus, (Control 3:1 and CD4+ depleted 4:1). This was not the same 
for the CD8+ depleted group where the proportion of mean bone to cartilage was 
1.5:1. Between the groups the mean percentage of bone in the callus was greatest in 
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the CD4+ depleted T lymphocyte group (45.3 %) compared to control (42.0 %) and 
CD8+ depleted (24.9 %), which was significantly different (p <0.001 95% CI 12.2 - 
28.6). Compared to control the CD8+ depleted group had significantly less mean 
percentage bone compared to the control (p < 0.001 95% CI 6.4- 23.7). The greatest 
mean percentage of cartilage in the callus was in the CD8+ depleted group (16.5 %). 
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7.3.8 IMMUNOCYTOCHEMISTRY 
Immunocytochemistry was used to identify leucocytes and more specifically, 
CD4 +and CD8+ T lymphocytes in mouse spleen. Analysis of the CD45R and CD3 
slides showed positive identification of leucocytes, early thymocytes and native T 
cells. Unfortunately both the CD8 and CD4 antibodies did not however identify any 
of the CD8+ and CD4+ T lymphocytes. 
7.3.9 DOUBLE LABELLED IMMUNOFLUORESCENCE USING CD4 AND 
CD8 PRIMARY ANTIBODIES 
To identify the presence of CD4+ and CD8+ T lymphocytes in mouse spleen the 
double immunofluorescence slides were analysed via a confocal laser microscope. 
CD8 antibodies were labelled with secondary antibody Streptavidin Alexa Fluor 633 
( red) and CD4 antibodies with Alexa Fluor 488 (green). CD4+ T lymphocytes were 
positively identified , figure 43A, compared to the control which was negative, figure 
43B. The CD8 Antibody control slide which contained only Alexa fluor 633 and no 
antibody was positive, figure 43C. As a consequence CD8+ T lymphocytes could not 






Figure 43: Double 
Immunofluorescence For 
CD4+ and CD8+ T 
lymphocytes Mouse spleen 
A) CD4+ identified by Alexa 
fluor 488 (green). B) Control 
of CD4 and CD8 with DAPI 
C) Control: Alexa fluor 633 
alone D) CD8+ cells 
identified by Alexa fluor 633 
with background staining 
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7.3.10 DOUBLE LABELLED IMMUNOFLUORESCENCE 
WITH TYRAMIDE 
No lymphocytes were identified when the slides were analysed using light 
microscopy with double immunofluorescence using tyramide for detection of CD4+ 
and CD8+ T lymphocytes. 
7.3.11 IMMUNOCYTOCHEMISTRY 
7.3.11.1 VARIATION OF ANTIBODY CONCENTRATION 
The analysis of the results from the variation in primary CD8 and CD3 antibody 
concentration with 30 minutes to overnight incubation time showed some interesting 
observations. No CD8+ T lymphocytes were identified at any primary CD8 
concentration at 30 minute incubation or overnight. In contrast CD3 +T lymphocytes 
were identified at a CD3 antibody concentration of 1:250 but only when incubated 
overnight. 
7.3.11.2 VARIATION IN FIXATION MATERIAL 
The results from the identification of both CD8 and CD3 T lymphocytes in spleen 
fixed with either formaldehyde or methacarn compared to tonsil are indicated in 





CONCENTRATIO FORMALDEHYD 1METHACAR TONSIL 




POSITIVE 1POSITIVE POSITIVE 
NEGATIVE POSITIVE 
Table IX : the detection of CD3+ and CD8+ T lymphocytes in spleen fixed in 
Formaldehyde or Methacarn compare to tonsil control. 
POSITIVE 
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The results from table IX showed that methacarn does not prevent the detection of 
either CD3+ or CD8+ T lymphocytes. Formaldehyde however, appeared to prevent 
detection of CD8+ T lymphocytes but not CD3+ T lymphocytes in spleen. 
7.3.12 DOUBLE LABELLED IMMUNOFLUORESCENCE USING CD3 
AND CD4 PRIMARY ANTIBODIES 
After the failures of the tyramide experiment and the lack of detection of CD8+ T 
lymphocytes using the double immunofluorescence or in the formaldehyde tissue it 
was decided to use a CD3 primary antibody instead of the CD8 antibody. The 
primary CD3 antibody was labeled with secondary antibody Streptavidin Alexa Fluor 
633 ( red) and CD4 antibody with Alexa Fluor 488 (green). Analysis of the double 
immunofluorescence with the confocal microscope showed the presence of CD4+ T 
lymphocytes ( green figure 44A /B) (yellow figure 44C). The CD3 antibody detection 
was negative as the control, figure 44B had non specific background binding and the 
merged slide, figure 44C had both not specific concentrated binding. 
A CD3 CONTROL B C 
Figure 44: Double Immunofluorescence For CD4+ and CD3+ T lymphocytes 
Mouse spleen A) Negative control (Alexa Fluor 488 and 5551, B) CD4+ 
Lymphocytes identified by Alexa Fluor 488 (green), C) Merged, CD4+ Lymphocytes 
identified by Alexa Fluor 488 (green, CD3+ T Lymphocytes identified by Alexa Fluor 
555 (red). 
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The experiment was then repeated using a different conjugated secondary antibody 
with the CD3 antibody, Alexa Fluor 555, to see if detection of CD4+ and CD8+ T 
lymphocytes in the paraffin embedded mouse spleen could be improved. The 
secondary antibody to the primary CD4 antibody remained Alexa Fluor 488. The 
CD4 T lymphocyte was positively identified compared to the control, figure 45B. 




Figure 45: Double Immunofluorescence For CD4+ and CD3+ T lymphocytes Mouse 
spleen A) CD4+ identified by Alexa fluor 488 (green) B) CD4 and Alex Fluor 488 with no 
CD3 primary antibody. merged. C) CD4 and Alexa Fluor 488 with CD3 and Alexa Fluor 633 
(CD4 cells in Yellow) 
As the CD3 antibody failed to identify T lymphocytes this primary antibody was 
changed to the Sigma C7390 CD3 antibody and the experiment repeated. Analysis of 
the slides showed positive detection of both CD3+ and CD4+ T lymphocytes in the 
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spleen samples compared to control but negative results with the bone samples, 
figures 46A /B. 
CONTROL A B 
Figure 46: Double Immunofluorescence For CD4+ and CD3+ T lymphocytes Mouse 
spleen and bone A) Negative control of spleen B) CD3+ ( red) and CD4+ T lymphocytes 
(green) identified 
Using a different bone sample the double immunofluorescence was repeated. 
Analysis using the confocal microscope showed the positive identification of the 
CD3+ T lymphocytes using the CD3 antibody but failure of detection of the CD4+ T 
lymphocytes figure 47 below. 
CONTROL A B 
Figure 47: Double Immunofluorescence For CD4+ and CD3+ T lymphocytes Mouse 







The successful depletion of both CD4+ and CD8+ T lymphocytes using antibodies 
was demonstrated to be a suitable method to study the effects of T lymphocytes in 
fracture repair. Sustained significant reduction of T lymphocytes in the fracture repair 
process was demonstrated confirming the longevity of the antibody inhibition 
method. The failure of complete depletion was a limitation of this method. However, 
the remaining numbers of T lymphocytes present were low. A critical threshold at 
which point the lymphocytes would resume a normal activity has not been reported. 
The maintained depletion of both CD8+ and CD4 +T lymphocytes throughout this 
study was considered sufficient to prevent normal action. This limitation could have 
been reduced if genetically bred mice, deficient in CD4+ or CD8+ T lymphocyte, 
were used. Yet both the costs and time of production of the mice limited there use. 
The clinical significance of the CD4 /CD8 depletion results are complex. If the CD4+ 
T lymphocyte depletion results for days 0 and 7 post fracture are compared to the 
WHO definition for HIV status, the group represents patients in stage IV disease 
(severe immunodeficiency, % CD4 <15 %), table II. Yet, comparing the CD4+ T 
lymphocyte levels at day14 and 2lpost fracture the group was associated more with 
stage III disease. In Rheumatoid arthritis the overall CD4+ T lymphocytes have been 
reported to be reduced by 17% within the synovial fluid compared to peripheral fluid 
tai Our experiment achieved greater levels of depletion in the peripheral circulation 
compared to this. (However, its subsets of CD4 +T lymphocytes behaved differently 
with TH 17 increasing and TH1, TH2 and TH3 decreasing). 
The clinical significance of isolated depletion of CD8+ T lymphocytes has not been 
specifically reported except in Rheumatoid arthritis. A recent study by Cho et al 
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described the levels of CD8+ T lymphocytes was inversely related to disease 
severity. The actual amount of CD8+ T lymphocyte depletion was not detailed in the 
study but the depletion achieved in this thesis would represent a patient with active, 
severe RA disease. 
8.2 IMMUNOCYTOCHEMISTRY 
The early experiments to identify CD4+ and CD8+ T lymphocytes in spleen failed at 
detecting CD8+ T lymphocytes. One hypothesis for this failure of detection was that 
the spleen fixative solution, formaldehyde, could have prevented the CD8+ T 
lymphocyte detection. A study by Leong and Gilham 203 showed the effect of 
formaldehyde on detection of tissue antigens . They showed that monoclonal 
antibodies could not be detected in certain tissue after 1 day of formaldehyde 
fixation. Formaldehyde acts by denaturing proteins, which is achieved by the 
irreversible binding of an extra amine group onto proteins or DNA. 
The results demonstrated in table XI Section 8.3.10.2 support those of Leong and 
Gilham by demonstrating that the failure of detection of CD8+ T lymphocytes could 
be accounted for by the formaldehyde fixation. This important result came at a late 
stage in the thesis experiments when all tissue, spleen and bone, had been preserved 
in formaldehyde. As a consequence tyramide was used in the double 
immunofluorescent experiments to amplify any possible detection of lymphocytes. 
The primary CD8 monoclonal mouse anti -human antibody was also changed to a rat 
CD3+ monoclonal antibody. The CD3+ monoclonal antibody would detect the 
general CD3 pan T lymphocyte marker 204. When then used in combination with the 
CD4 antibody in the double immunofluorescent experiments it would allow the 
identification of both CD4 and CD8 T lymphocytes. 
By changing the primary rat CD3 antibody for a second time to a rabbit CD3 
antibody it was possible to use double immunofluorescence to identify both CD4+ 
144 
and CD8+ T lymphocytes in the spleen samples. Unfortunately simultaneous double 
immunofluorescence of the fracture callus failed to identify CD4+ T lymphocytes. 
This was thought to be also due to the formaldehyde fixation inhibiting the 
immunostaining. 
8.3 CD4+ T LYMPHOCYTES 
The mean callus formation results suggested that between days 7 and 14 CD4+ T 
lymphocytes had an inhibitory effect on fracture repair. Mice depleted in CD4 +T 
lymphocytes were shown to have a significant increase in callus formation at day 14 
post fracture compared to controls (section 7.3.2). This was also evident in the CD8+ 
depleted group at day 14. Here the amount of callus formation was significantly less 
compared to the CD4+ depleted group. These results support the published evidence 
that CD4+ T lymphocytes have a role in controlling fracture repair 82,128. Yet these 
studies did not define whether there was a negative or positive effect on fracture 
repair. In this study the inhibitory effect of the CD4+ T lymphocytes was most 
evident between 7 and 14 days post fracture. By day 21 there was no further 
significant increase in callus formation in the CD4+ depleted group. This time frame 
of 7 -14 days had been shown in previous studies to be when lymphocytes are present 
in the fracture site and could represent the acquired inflammatory phase of fracture 
repair 82. 
As previously described CD4+ T lymphocytes are involved in osteoclastogenesis 
either directly via RANKL on indirectly via TNfF a. , Section 3.3.5, figure 4. Kong et 
aP 15 study reported the systemic activation of T cells in vitro led to an RANKL 
mediated increase in osteoclastogenesis and bone loss. Using a T cell dependent 
model of adjuvant rat arthritis their in vivo study showed inhibition of RANKL by 
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OPG at the onset of the disease reduced clinical signs of arthritis, with less cortical or 
trabecular bone loss, and reduced numbers of osteoclasts compared to controls 115. 
Further studies have implicated TH17, a subset of CD4+ T lymphocytes, in the 
aetiology of autoimmune bone diseases such as Rheumatoid arthritis 117. Sato et al12° 
have reported that TH17 express RANK and so can directly effect osteoclastogenesis. 
It can be speculated that in this study depletion of CD4+ T lymphocyte may have 
also depleted these TH17 lymphocytes, leading to a reduction in osteoclastogenesis 
and increase in fracture repair. 
Additionally the cytokines produced by the CD4 + Lymphocyte could inhibit cell 
recruitment and the fracture repair process itself. TH17 lymphocytes also secrete the 
cytokine IL -17, which can induce inflammation and activate macrophages to produce 
pro -inflammatory cytokines like TN- a, IL -1 and IL -6 117,120 These cytokines can 
either directly or indirectly activate osteoclasts causing accelerated 
osteoclastogenesis 117. In this study the depletion of CD4+ lymphocytes may have 
reduced the overall level of cytokines produced, leading to a decline in 
osteoclastogenesis and increase in fracture repair. 
A similar affect of increased callus formation has been shown in studies using 
bisphosphonates. Bisphosphonates are a class of medication which are used in 
Osteoporosis to prevent bone loss. Cellularly their mechanism of action is targeted at 
the osteoclast, leading to reduced osteoclast activity, adhesion and apoptosis 205. An 
in vivo study by Li et al 206 investigated the affect of incadronate on the early stages 
of fracture healing in rats. They demonstrated a significantly larger callus in the 
group that received the largest continuous dose of incadronate during the 4 weeks of 
the experiment compared to the control (p <0.05) 206 
Interestingly CD4+ T lymphocytes' inhibitory action on fracture repair was also 
demonstrated in the non union fracture study by Santavirta et al 207. They 
investigated the composition of fractures which had either gone onto delayed union 
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or non union in patients 4 -24 months post fracture. The delayed fracture callus 
material was found to have a higher proportion of inflammatory cells, in particular 
CD4 +T lymphocytes. These were present in twice as many numbers as CD8+ T 
lymphocytes. 
Overall the mean callus results suggested that CD4+ T lymphocytes had an inhibitory 
role in fracture repair critically between days 7 to 14 post fracture. To investigate 
whether the resulting rapid callus formed in the CD4+ depleted group was more 
advanced and mature than both the CD8+ depleted and control groups at day 21, the 
composition of the callus was examined. Stereology results from the fracture callus 
at day 21 confirmed a greater mean percentage of bone in the depleted CD4+ T 
Lymphocyte group compared to the control and CD8+ depleted groups (p <0.001). 
There was also significantly less cartilage in the CD4+ depleted group compared to 
the CD8 + depleted group (p <0.05) at day 21. These results suggested that the final 
fracture callus in the CD4+ depleted group was similar to controls. The accelerated 
mean callus formation seen radiographically in the CD4+ depleted group at day 7 
and 14 was considered to have more advanced, mineralisation than controls. This 
could not be confirmed due to the limitations of the study numbers. However future 
stereology of the fracture callus at day 7 and 14 post fracture could confirm this. In 
the current study the mean callus to femur bone pixel density results at days 14 and 
21 and mean callus density at day 21 were used to identify any advancement in the 
fracture repair process in the CD4+ depleted group. Although no significant 
difference was found between the 3 groups. The absence of significance could have 
been due to the variation in the quality of the radiographic images produced. These 
were originally produced by chemically processing rather than digitally. Converting 
these radiographic images to digital by camera could also have added a variation in 
spatial resolution, depth, detail and quality. This could have been reduced if a 
transparency adapter to the flat bed scanner was available or digital radiographs were 
used from the onset. Unfortunately both of these were unavailable at the time of the 
study. 
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The mechanical 4 point bending results of the CD4+ depleted fractures callus at day 
21 suggested there was no increase in bone stiffness. Both extrinsic and intrinsic 
properties were similar to that of controls. The lack of significant difference in the 
CD4+ depleted group could have been a result of the small number of animals per 
group. Repeating the study with greater numbers in each group would identify if 
there was a relevant difference. Additionally the mean callus density and stereology 
could be repeated blinded by 2 observers to avoid observational bias. In this study 
they were analysed unblinded by one observer. 
Overall the in vivo results suggested that CD4+ T lymphocytes have a specific 
controlling role in fracture repair, particularly inhibitory at day 7 -14 post fracture. 
Early fracture repair was accelerated in this study when CD4+ T lymphocytes were 
depleted. 
8.4 CD8+ T LYMPHOCYTES 
The results of the callus formation in the CD8+ depleted T lymphocytes group at day 
14 showed no significant difference in the callus size compared to control. At day 21 
the CD8 + depleted group showed a significant increase in the size of the callus 
compared to both the control and CD4+ depleted groups. However the stereology 
results at day 21 demonstrated that the callus produced in the CD8 + depleted group 
had both a greater mean percentage of cartilage and a reduced mean percentage of 
bone compared to the control and depleted CD4+ groups. The larger amount of 
cartilage present implied the fracture repair process had been delayed. The fact that 
this was not case in the CD4 + depleted group where they were present is an 
important observation. 
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The timeframe of the experiment (i.e.up to a maximum of 21 days) meant that it was 
impossible to distinguish between delayed union and non union. Is is possible that if 
the animals had been kept alive for an extended period the fractures would still have 
failed to bridge with bone and progressed to established non union. However, the 
delayed healing observed in elderly patients who are known to have decrease CD8 + 
T lymphocyte levels would suggest that the CD8+ depleted mice in this experiment 
exhibit delayed healing rather than non union. 
These results suggest that CD8 + T lymphocytes are not only essential to the fracture 
repair process but they have an advantageous role. This beneficial action could be 
due to the CD8+ T lymphocytes themselves of an effect from their cytokines. 
Evidence exists for the regulation of CD4+ T lymphocytes by CD8+ T lymphocytes 
184,208 Jiang et al 184 investigated the in vivo effect on T cell vaccination of 
experimental autoimmune encephalitis (EAE) in B l OP female mice depleted of 
CD8+ T lymphocytes compared to controls. EAE was an animal model of human 
multiple sclerosis 184. They depleted CD8+ T lymphocytes in one group using CD8+ 
antibodies 10 days prior to immunisation of EAE. Both the CD8+ depleted and 
control groups were given 8 -12 weeks to recover before a second induction of EAE. 
They found that mice depleted in CD8+ T lymphocytes had a greater susceptibility to 
EAE after a second exposure to EAE compared to undepleted controls 184. They 
concluded that CD8+ T lymphocytes were required in the primary exposure to 
become primed so as to allow the down regulate of EAE CD4+ T lymphocytes 
during the second exposure 184. In addition they identified an increased 
predominance of TH1 CD4+ lymphocyte in EAE mice given injections of CD8+ T 
lymphocytes compared to controls. They summarised that CD8+ T lymphocytes 
selectively regulated TH1 T lymphocytes 184. It can be postulated that in this thesis 
the depletion in CD8+ T lymphocytes may have led to a reduction in regulation of 
TH1. This may have contributed to an overall increase in TH2 and TH17 lymphocytes 
levels. With the result more IL -17 may have been produced during the fracture repair 
process. IL -17 has been reported to activate the maturation of osteoblasts 209. Such an 
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action could possibly explain why the depleted CD8+ callus had more cartilage to 
bone on stereology testing. Future studies to identifying TH17 and measure IL -17 
would clarify this. 
The beneficial role of CD8+ T lymphocytes in fracture repair is a new finding which 
appears to contrast published data on its role in wound healing. Davis et a1132 studied 
wound repair in rats depleted in CD4+ and CD8+ T lymphocytes. They found CD8+ 
T lymphocytes down regulated wound healing with their absence leading to a 
stronger wound. This difference in roles could be due to the fact that fracture healing 
is scarless compared to wound healing, such that fracture is repaired with bone rather 
than a scar. 
The scar in wound healing is derived from fibroblasts. During the inflammatory 
phase of wound healing, they migrate to the wound by chemotactic control from 
macrophage cytokines and growth factors 210. Here they proliferate and secrete 
collagen type III 211. This is then converted to type I collagen 211. In contrast in 
fracture healing, chondrocytes derived from mesenchymal progenitors cells 
proliferate and synthesise type II collagen 21. This collagen forms soft callus at the 
fracture site, section 3.1.2. Mature osteoblasts are then stimulated to produce type I 
collagen in the form of woven bone 31 
One hypothesis that could explain the observed difference between the roles of 
CD4 + /CD8+ T lymphocytes in wound and fracture healing could be the different 
target cells i.e. fibroblasts vs osteoblasts, figure 48. Although both of these cells 
originate from the same mesenchymal stem cell they are stimulated to mature by 
different cytokines. Nam et al 209 reported on the influence of IL -17F on stimulating 
the maturation of osteoblasts. They observed an increase in osteoblastic bone 
markers when primary mesenchymal stromal cells were incubated in IL -17F culture 








Figure 48: Diagram of the possible action of Lymphocytes and their cytokines on 
different target cells leading to wound or fracture healing. Tx/Ty = different T 
lymphocytes, Cyto X/Y= T lymphocyte cytokines, Fb= Fibroblast cell, OB= Osteoblast 
In contrast Till lymphocytes have been found in healing wounds 212. Their cytokines, 
particularly IFNy, are known to stimulate macrophage production of nitrous oxide 
213. Studies have shown depletion of nitrous oxide leads to impairment in re- 
epithelialisation of wounds, decreases collagen deposition and decreases rate of 
closure of full thickness wounds 214. If there is a difference in local cytokines in 
wound healing and fracture repair effecting the T lymphocytes differently in the 2 
locations, this could account for the different responses, figure 49. Alternatively the T 
lymphocytes in both environments may produce the same cytokines but the receptor 
on the fibroblast and osteoblast may result in a different repair, figure 50. In this 
study the level and type of cytokines at the fracture site were not measured. This was 
a limitation of the study as the importance of cytokines in osteoblastic stimulation 







Figure 49: Diagram of the possible action of local environment cytokines on T 
lymphocytes and their subsequent production of cytokines acting differently on target 
cells. Cyto1 /2 = location cytokines, Tx= T lymphocyte, Cyto X -= T lymphocyte Cytokine X 





Figure 50: Diagram of possible action of environment cytokines on T lymphocyte 
cytokine production and their selective action on target cells due to specific 
receptors. Cyto 1/2= Environment Cytokines, Tx= T lymphocytes, Cyto X= T lymphocyte 
cytokine, Fb= fibroblasts, OB= osteoblasts 
The mean callus: femur pixel callus bone density ratio at days 14 and 21 post fracture 
and mean callus density at day 21 in the CD8+ depleted group was the lowest 
amongst the 3 groups. This low trend, although not significant, implied that the 
callus formed was at a earlier stage of repair compared to the other 2 groups. This 
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trend also reflects the findings with stereology. However to confirm that the callus 
was maturing at a slower rate stereology should be performed at days 7 and 14 post 
fracture. This was not performed due to the low numbers within each group. 
The mechanical 4 point bending results reinforced the Stereology observations. The 
CD8+ depleted group had a lower yield point, a greater displacement, with a lower 
stress and stiffness compared to the control and CD4+ depleted group. These results 
are in keeping with the increased cartilage to bone ratio within the CD8+ depleted 
group. 
Overall the in vivo study suggested that CD8+ T lymphocytes have an essential 





Through preclinical studies this thesis has investigated aspects of the effect of the 
immune system on fracture repair. Both a histological and mechanical approach was 
taken to identify in vivo, the role of CD4+ and CD8+ T Lymphocytes on fracture 
repair. This incorporates the use of FACS, radiology, 4 point bending, stereology, 
histology, and immunocytochemistry techniques. It also allowed the development of 
antibody depletion models not previously used to investigate the fracture repair 
process. 
Using the above methods, described in chapter 2, the following null hypotheses were 
addressed; 
1) There was no difference on the fracture repair process in animals who had been 
depleted of CD4+ and CD8+ T lymphocytes. 
2) There was no difference on the fracture repair process in animals who had been 
T compared to immune competent controls. 
3) There was no difference on the fracture repair process in animals who had been 
depleted of CD8+ T lymphocytes compared to immune competent controls. 
Focussing on the in vivo studies and the first null hypothesis this thesis has indicated 
that both CD4+ and CD8+ T lymphocytes are important in fracture repair, although 
their roles were different. The mean callus size at days 14 and 21 were significantly 
different; more callus was identified in the depleted CD4+ group at day 14 whilst at 
day 21 the depleted CD8+ group had more callus (p <0.05 955 CI 34- 2216). The 
mean callus: femoral shaft pixel density ratios showed a trend for the depleted CD8 
group to have a lowest value yet this was not statistically significant. The lack of 
significance could be due to variation in detail and resolution of the digital images 
taken. Although standardisation were used for all the images taken the film 
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radiographs were varied in their resolution and quality. Using digital radiographs 
would of improved the overall quality and data analysis but these were not available 
at the time. 
Mechanical 4 point bending indicated that the depleted CD8+ group had overall 
lower yield point, ultimate stress, and young's modulus compared to the depleted 
CD4+ group but this was not statistically significant. The failure to detect a 
significant difference could have been to the low numbers in the study with n =5. The 
stereology results reinforced the mean callus data and confirmed a statically 
significant difference between the groups; depleted CD8+ group had more cartilage 
(p <0.005) and less bone (p <0.01) compared to the depleted CD4+ group. Yet as only 
one unblinded observer was used to analyse the data observational bias could have 
played a role in these results. Overall these results suggest that there is a significant 
difference between CD4+ and CD8 + T lymphocytes in the process of fracture repair. 
The first null hypothesis can be rejected. 
Concentrating on the depleted CD4+ group the radiological mean callus formation 
suggested that CD4+ T lymphocytes inhibited fracture repair around day 7 -14 post 
fracture (p <0.001 compared to controls). Yet stereology and mechanical testing on 
day 21 post fracture suggested this inhibitory role was absent, with results of the 
CD4+ depleted group to be similar to that of controls. No statistically significance 
was identified. The Stereology may have been effected by observational bias. The 
observations that CD4+ T lymphocytes inhibit fracture repair is in contrast to their 
potential advantageous role in wound healing 
thus rejected. 
132,215. The second null hypothesis was 
These results suggested an the inhibitory action of CD4+ T lymphocytes but this 
appeared to be fracture time dependent. Further studies, particularly stereology, in 
the early process of fracture repair would confirm this inhibitory role. This inhibition 
on fracture repair could be caused by CD4+ T lymphocytes action on osteoclasts and 
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osteoclastogenesis. Another important role could be that of the cytokines produced 
by the CD4+ T lymphocytes which could inhibit cell recruitment and the fracture 
process itself. 
With reference to the CD8+ T lymphocyte results the mean callus radiographs were 
statistically increased compared to controls at day 7 (p <0.001) and day 14 post 
fracture (p <0.005). Stereology confirmed this with greater cartilage (p <0.05) and less 
bone (p <0.01) compared to controls. Although not statically significant, the 
mechanical testing results suggested a weaker and less stiff fracture callus compared 
to controls. Overall in all, the results suggested that CD8+ T lymphocytes have a 
beneficial role in fracture repair and the third null hypothesis can be rejected. This is 
in contrast to their documented inhibitory role in wound repair 132. 
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9.1 CLINICAL RELEVANCE 
Concentrating on the clinical significance of this thesis. The results of this thesis 
have implications to those patients who have CD4+ immunodeficiencies and suggest 
that the absence of CD4+ T lymphocytes would lead to an enhancement of fracture 
repair. Unfortunately evidence of fracture repair in complete Di George patients is 
lacking so this assertion has not yet been confirmed in these patients. In contrast in 
HIV patients a delay in fracture repair rather than a benefit has been reported 154,160. 
One explanation of this could be due to the rise in infection rates in patients with 
HIV due to reduction in CD4+ T lymphocyte levels 154,216 However a larger 
prospective blind study by Harrison et al 217 reported the incidence of infection in 
HIV positive patients with closed fractures to be similar to seronegative controls 
(3.5% vs 5% p <0.4) . 
As previously described in section 3.2.2.5 non union is associated with open 
fractures due to soft tissue damage and infection. Evidence suggests that HIV 
positive patients are 5 times more likely to develop infection from open fractures 
than seronegative patients 217 and with it an increased risk of fracture non union. This 
has important clinical implications particularly in Sub -Saharan Africa where the 
incidence of HIV and road traffic related fractures continues to rise 160. Commonly 
the fractures are open for which urgent surgical debridement, fracture stabilisation 
and antibiotics are the gold standard treatment. Complicated by poor road transport 
and few medical services frequently these patients present late to the referral hospital 
with established infections and fracture malunion or non union 
160. 
In addition HIV, as described in section 4.1.2.1, is a complex disease which can 
effect other cells of the immune system. These cells maybe required for the fracture 
repair process; for instance the CD8 + T lymphocytes cytotoxic action is impaired in 
HIV 149. The in vivo results of this study support the postulate that an increase in 
fracture non union in HIV patients could be due to the lack of active, regulatory 
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CD8+ T lymphocytes rather than CD4+ T lymphocytes: i.e. the beneficial action of 
CD8+ T lymphocytes in fracture repair is absent. Combined with the reduced number 
of CD4+ T lymphocytes it is conceivable that the regulatory control and production 
of cytokines to . stimulate fracture repair would be reduced. 
Restoring the level of CD4+ and CD8+ T lymphocytes in the fracture repair process 
could encourage near normal fracture healing. The medication of high active anti - 
retroviral therapy (HAART) in HIV patients in the western world aims to restore this. 
There is limited evidence for HIV positive patients with fracture non union on these 
medications which suggests that further research is warranted. 
The results of this in vivo study could have clinical significance for patient with 
Rheumatoid arthritis As previously discussed in chapter 4.1.2.2, RA is a chronic 
inflammatory arthropathy characterised by the presence of an increase number of 
TH17 T lymphocytes in the joint synovium. This increase in levels of TH17 
lymphocytes and their cytokines could be one explanation for the increased non 
union rate in the RA patients. Very little previous work is relevant for determining 
the role of CD4+ T lymphocytes in fracture repair. Recent in vivo studies involving 
fracture repair in knockout mice deficient in T and B lymphocytes confirmed a 
mechanical stronger fracture callus at days 14 and 21 compared to controls 102,194. 
The relative bone mineral density was also significantly greater in the immune 
deficient groups (p <0.001)194, (p <0.05)102. In addition histological analysis of the 
fracture site at days 1,3,7,14 and 21 post fracture revealed a faster fracture repair in 
the Severe Combined Immunodeficient mice tibiae, with more rapid progression 
through cartilage, woven and then lamellar bone formation compared to the immune 
component controls 194 Although both T and B lymphocytes were depleted in these 
models these results proposed that the acquired immune system had an inhibitory 
role on fracture repair. Further work by Colburn et al 99 investigated specifically the 
role of gamma delta T lymphocytes on fracture repair. Mice deficient in gamma delta 
T lymphocytes demonstrated histologically a smaller more mature advanced callus at 
day 5 post fracture with increased expression of bone and cartilage compared to 
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controls. However these differences were not maintained as the callus matured. 
Mechanically the gamma delta T deficient mice maintained a significant higher 
maximal load (p= 0.0002), stiffness (p= 0.05) and elastic modulus (p =0.05) 4, 6 and 8 
weeks post fracture compared to controls. If CD4+ T lymphocytes were also to have 
an inhibitory effect on fracture repair then this would account for the increase in non 
union rate in rheumatoid arthritis. 
However, the altered immune system is only one factor in Rheumatoid Arthritis 
patients which may alter the fracture repair process. The majority of these patients 
are on medication that modify the immune system and effect fracture repair. 
NSAIDS are one example inhibit cyclooxygenase (COX) activity and prevent 
production of prostaglandins. Although conflicting evidence exists, the majority have 
shown NSAIDS effect the inflammatory phase of fracture repair leading to delayed 
union 31. Further in vivo studies have shown a significant reduction in mechanical 
strength, and delay in maturation of the fracture callus in rodents given NSAIDS 
compared to controls 49 -51. DMARDs, for example methotrexate, are another type of 
medication used by RA patients. Evidence is scarce on its influence on fracture 
healing. Only one small study exists on fractures in children with acute lymphocytic 
leukemia 57. They describe the development of non union in 3 patients (42 %) who 
were on methotrexate57. 
This thesis has highlighted the pivotal role of the acquired immune system in fracture 
repair in a variety of diseases (e.g. RA, HIV and DiGeorge), as well as many drugs 
(e.g. NSAIDS, DMARDs), which are known to affect the acquired immune system 
and the fracture repair process. By being aware of the increased risk of impaired 
healing Orthopedic surgeons can review patients more closely (e.g. early ultrasound 
or CT) so that they can intervene at an early stage. In order to reduce both the pain 
and disability associated with impaired fracture healing. 
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10.0 FUTURE WORK 
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10.0 FUTURE WORK 
The results from this thesis have suggested future in vivo work would concentrate on 
the early stages of the fracture repair process from day 0 -14 post fracture. As the 
depletion method was successful this would be repeated for all 3 groups. However all 
the tissue samples would be preserved in methacarn and not formaldehyde. The 
experiment would concentrate on the histological constituents of the fracture callus 
by stereology, histomorphometry and microstructure of the callus using µCT now 
available in the laboratory 102. These methods would allow the fracture callus from 
the depleted CD4+ T lymphocyte to be studied and any rapid, advanced callus 
formation identified. This would then answer the question of whether CD4+ T 
lymphocytes were inhibitory in the early phases of fracture repair. Repeating this 
study would also allow the depleted CD8+ T lymphocyte fracture callus to be further 
examined to see if the fracture callus was inferior and delayed compared to controls. 
This would confirm the advantageous role of CD8+ T lymphocytes in fracture repair. 
Additional immunocytochemistry methods to measure the amount of collagen II, 
expressed by chondrocytes, compare to collagen X, hypertrophie 
chondrocytes during endochondral ossification, would add more confirmation of 
fracture maturity in the 3 groups 102. 
To confirm the different roles of CD4+ and CD8+ T lymphocytes in fracture repair 
`Add -back' experiments would be preformed at day 14, introducing either CD4+ or 
CD8+ T lymphocytes. Any resolution of abnormality within the fracture callus with 
the levels of T lymphocytes restored should reinforce their individual roles. 
During the original experiments no cytokines level was measured during the fracture 
repair process. Recent work by Toben et al 102 have suggested these vary throughout 
the stages of fracture repair. Therefore to fully investigate the role of CD4+ and 
CD8+ T lymphocytes, the level of their cytokines would be measured. These would 
include TNF alpha, IFN ,lymphotoxin- ß(LB -ß), IL -2 IL- 4,IL -10, IL -17. 
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Strategic Immunological Solutions 
MAC 51 MAC 51 
Antibody: AFRC MAC 51 
Batch: AS00306SU 
Test: Binding efficacy to murine T cells 
Date: 27/10/06 
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10° 10' 102 100 
FLI LOG: FL1 LOG 
Thymocytes 
Antibody (culture supernatant) was tested 
against balb /c thymocytes and splenocytes by 
indirect immunofluorescence. 
Thymocytes: Cells not stained. 
Splenocytes: Cells not stained 
Titration (shown using thymocytes but identical 
results with splenocytes): No labelling even at 
100tig /ml. This antibody fails to bind T cells 
even at very high concentration. 
Note: These data are provided as a guide. User 
should always determine optimum concentration 
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CD4 ANTIBODY (YTS 191.1.1.2) BINDING ABILITY TO 
T LYMPHOCYTES o 
immunoSolv 
Strategic Immunological Solutions 
YTS 191 YTS 191 
Antibody: YTS 191.1.1.2 
Batch: AS00406SU 
Test: Binding efficacy to murine T cells 
Date: 27/10/06 
a 
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, .., 100µg /ml 
1d 1O' log 10' 10e 10° 
FL1 LOG. FL1 LOG 
Thymocytes 
Antibody (culture supernatant) was tested 
against balb /c thymocytes and splenocytes by 
indirect immunofluorescence. 
Thymocytes: Vast majority of cells positively 
stained (note most thymocytes in the 
preparation are double positive CD4 +CD8 +). 
Splenocytes: Positive and (minor population) 
negative populations. 
Titration (shown using thymocytes but identical 
results with splenocytes): Excellent saturation 
labelling as low as 1 t1g /ml with no diminution as 
compared with 1OO11g /ml. Potent antibody 
preparation in this assay (saturation normally 
expected around 10äg /ml). 
Note: These data are provided as a guide. User 
should always determine optimum concentration 
of each batch of antibody for own applications. 
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Antibody: YTS 169.4.2.1 
Batch: AS00206SU 




103 10'' 100 00' iO3 103 
FL1 LOG: FL1 LOG 
Thymocytes 
Antibody (culture supernatant) was tested 
against balb /c thymocytes and splenocytes by 
indirect immunofluorescence. 
Thymocytes: Vast majority of cells positively 
stained (note most thymocytes in the 
preparation are double positive CD4 +CD8 +). 
Splenocytes: Positive and negative 
populations. 
Titration (shown using thymocytes but identical 
results with splenocytes): Excellent saturation 
labelling as low as 1µg /ml with no diminution as 
compared with 100í1g /ml. Potent antibody 
preparation in this assay (saturation normally 
expected around 10µg /m1). 
Note: These data are provided as a guide. User 
should always determine optimum concentration 
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ADMINISTRATION OF BUPRENORPHINE 
Table XI below shows the doses of buprenorphine given 





























































Drug Amount Date & Time 
Table XI, Post operative chart for monitoring mice. *Bodyweight was best 
assessed by regularly weighing the animal, daily and more often when weight loss is 
suspected. E.g. rodents that have lost a significant amount of weight usually have a 
protruding backbone, square tail and pointy face. A moderate severity limit would usually 
involve a maximum body weight loss if 20 %. * *For weight bearing in the fractured limb a 
comment was made: Normal, Placing foot, Lifting foot, Dragging. 
If a score of 6 is seen and body weight drops by >20% then Named Veterinary Surgeon 




HAEMATOXYLIN AND EOSIN (H&E) STAINING PROTOCOL 
1) Slides placed in oven overnight at 55 °C 
2) Slides were then de -waxed and rehydrated using - 
Xylene 1 for 5 minutes 
Xylene 2 for 5 minutes. 
100% Alcohol 2 minutes. 
100 Alcohol 2 minutes. 
80% Alcohol 2 minutes. 
50% Alcohol 2 minutes. 
3) Washed in running water 2 minutes. 
4) Staining- slides placed into Haematoxylin for 5 minutes. 
5) Removed and washed in running water. 
6) Differentiated for 5 seconds maximum in 1% Acid alcohol 
(70% alcohol, 1% concentrated HCL). 
7) Transferred to dish of Scott's tap water substitute for 2 mins until the 
tissue sections turn blue. 
8) Slides placed in the Eosin solution stain for 2 minutes. 
9) Removed and wash in running water briefly. 
10) Dehydrated by placing in 50% Alcohol for 30 seconds. 
11) 80% Alcohol for 30 minutes. 
12) 100% Alcohol for 2 minutes. 
13) 100 % Alcohol for 2 minutes. 
14) Xylene 5 minutes. 
16) Xylene 5 minutes. 
17) Slides mounted in DPX. 
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TOLUENE BLUE STAINING PROTOCOL 
1) Slides placed in 1% Toluene blue for 10 mins 
2) Washed with PBS xl, 5 minutes per wash 
3) Slides dried off on filter paper 
4) Mounted using aqua mount 
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SINGLE LABELLED IMMUNOHISTOCHEMISTRY PROTOCOL 
Preformed using the Dako Envision TMKit (K4004, Dako Ltd, UK) 
Antibody concentration 1:100 
Antibodies: 
CD3 (Rat monoclonal Cat no VP- C317, Vector Ltd CA 94010) 
CD45R (Purified Anti -Mouse Cat No OT121D, Pharmingen) 
CD8 (Mouse Antihuman Cat no M7130, DakoCytomation, Denmark) 
CD4 (Mouse Antihuman Cat no VP -C -319, Vector Ltd CA 94010) 
1) 4 slides with mouse spleen were incubated for 10 minutes at 60 °C degrees 
2) The slides were dewaxed by decreasing concentrations of Xylene and washed 
3) Antigens retrieved by placing slides in an autoclavable pressure cooker with 
Borg decloaker solution ph5 (Boiocave Medical, cat no BD 1000MM) 
covering them. 
4) The pressure cooker was then placed in a microwave, and heated for 2 
minutes when the optimal pressure had been reached. The pressure cooker 
was then left to cool for 10 minutes before the slides were removed. 
5) The slides were washed xl in running water for 5 minutes. 
6) The slides were then placed in Shandon Sequenza R cover plates. 
7) 3 drops (approximately125uL) of peroxidase block (Dako Ltd, UK) were 
then added to each slide and incubated for 5 minutes. 
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8) The sides were then washed 3 times with PBS. 
9) The primary antibody was diluted with antibody diluent (Dako Ltd, UK) to a 
concentration of 1:250, and 125µl was added to each slide and incubated for 
30 minutes. 
10) The slides were then washed x3 with PBS. 
11) 3 drops of DAB substrate (Dako ltd, UK, K 3468)) were then added to each 
slide for 20 minutes. 
12) 3 drops of AEC and substrate Chromogen (Dako Ltd, UK) were then added to 
each slide for 30 minutes 
13) The slides were then washed x3 with distilled water. 
14) To counterstain the slides, initially they were placed in Haemoxylin for 30 
seconds and then washed in PBS. 
15) The slides were quickly dipped in acetyl alcohol and washed in PBS. 
16) The slides were then washed in Scott's tap water for 1 minute then washed 
xl in PBS 





















Stress Strain Young's 
modulus 
UoM (N) (mm) (mm) (mm) (mm) (mm) (mmSq) (N/ 
mmSq) 
Calc'd A B C D E =D /2 F =C /2 G =E x 
Fcubed x Pi/ 
4 
H =A x 
2F /2G 
1 =6F x B / 
56 





24.0 0.539 1.02 3.13 1.57 0.51 0.163 75.057 0.029 2,546.6 
control 
c2,0L 
43 2 0.371 1.12 4.27 2.14 0.56 0.294 82.067 0.022 3,683.7 
control 
c2,10L 




42.7 0.398 1.1 3.07 1.54 0.55 0.201 116.951 0.023 4,985.5 
control 
C3,2L 
51.6 0.614 1.68 4.3 2.15 0.84 1.001 43.271 0.055 783.6 
control 
c3,30L 
38.5 0.524 1.25 3.71 1.86 0.63 0.356 67.730 0.035 1,930.2 
Average 37.9 0.475 1.22 3.62 1.81 0.61 0.373 75.731 0.032 2,798.9 
Adjusted 
Ave 
37.9 0.475 1.22 3.62 1.81 0.61 0.373 75.731 0.032 2,798.9 


















Stress Strain Young's 
modulus 
UoM (N) (mm) (mm) (mm) (mm) (mm) (mmSq) (N /mmSq) 
Calc'd A B C D E =D /2 F=C/2 G =5 x 
Fcubed x 
Pi /4 
H =A x 2F/ 
2G 







38.4 1.380 3.88 5.23 2.62 1.94 14.996 4.972 0.287 17.3 
control 
c2,0R' 
43.0 0.341 4.23 6.21 3.11 2.12 23.072 3.940 0.077 51.0 
control 
c2,10R' ll 63 0755 448 527 264 224 23260 0 605 0 181 33 
control 
c3,0R' 
27.3 1.053 5.09 5.87 2.94 2.55 37.998 1.831 0.287 6.4 
control 
c3,2R* 
51.6 0.614 4.69 536 2.68 2.35 27.143 4.454 0.154 28.9 
control 
c3,30R' 
5 0.812 4 61 5.73 2.87 2.31 27 557 0 670 0 201 3 3 
Average 29.1 0.826 4.50 5.61 2.81 2.25 25.671 2.746 0.198 18.4 
Adjusted 
Ave 
40.1 0.847 4.47 5.67 2.83 2.24 25.802 3.800 0.201 25.9 

















Stress Strain Young's 
modulus 
UoM (N) (mm) (mm) (mm) (mm) (mm) (mmSq) (N /mmSq) 
Calc'd A B C D E =D /2 F =C /2 G =E x 
Fcubed x 
Pi /4 
H =A x 2F/ 
2G 





cd4 c1,1111 34.1 0.610 1.65 1,45 0.73 0.83 0.320 88.103 0.054 1,633.7 
cd4c1.3L 41.8 1.258 1.62 1.33 0.67 0.81 0.278 121.978 0.109 1,117.7 
cd4 
cl,30L 
7 0.524 1 04 1 14 0.57 0.52 0.063 47 275 0 029 1,619 6 
cd4 c2.0L :- ? 0 443 1 67 1.75 0.88 0.84 0.400 5.554 0.040 140 2 
cd4 c3,1L 33.6 0.497 1.32 2.22 1.11 0.84 0.508 55.202 0.044 1,242.4 
cd4 C3,3L 34.5 0.569 1.99 2.33 1.17 0.66 0.263 86.629 0.040 2,151.5 
Average 25.4 0.650 1.55 1.70 0.85 0.75 0.305 67.457 0.053 1,317.5 
Adjusted 
Ave 
36.0 0.733 1.65 1.83 0.92 0.78 0.342 87.978 0.062 1,536.3 



















Stress Strain Young's 
modulus 
UoM (N) (mm) (mm) (mm) (mm) (mm) (mmSq) (N /mmSq) 
Calc'd A B C D E =D /2 F =C /2 G =E x 
Fcubed x 
Pi /4 
H =A x 2F/ 
2G 
1 =6F x B / 
56 






35.0 0.801 4.28 5.65 2.83 2.14 21.745 3.448 0.184 18.8 
cd4 
c1,31=1" 
' 5.7 0.551 501 
465 233 251 28 704 0496 0 148 34 
cd4 
c1.30R* ' 
50.5 1.414 4.62 7.56 3.78 2.31 36.595 3.189 0.350 9.1 
cd4 
QFj',. 
53.1 1.222 4.86 5.66 2.83 2.43 31.893 4.049 0.318 12.7 
Apit:c4. 
C3,114* 
58 7 1.158 4.85 6.74 3.37 , 2.43 37.745 3.768 0.301 12.5 
cd4 
c3,3R' 
14 7 0.849 3.87 4.71 2.36 1.94 13.401 2.127 0.176 12.1 
Average 36.3 0.999 4.58 5.83 2.91 2.29 28.347 2.846 0.246 11.4 
Adjusted 
Ave 
42.4 1.089 4.50 6.06 3.03 2.25 28.275 3.316 0.266 13.0 


















Stress Strain Young's 
modulus 
UoM (N) (mm) (mm) (mm) (mm) (mm) (mmSq) (N /mmSq) 
Calc'd A B C D E =D /2 F =C /2 G =E x 
Fcubed x 
Pi /4 
H =A x 2F/ 
2G 
1 =6E x B/ 
56 
J =AB x 
4/12G x 
28 
cd8c1,1L 36.9 0.552 1.48 1.6 0.80 0.74 0.255 107.368 0,044 2,454.9 
cd8 
c1,30L 
37.8 0.494 1.52 1.62 0.81 0.76 0.279 102.903 0.040 2,559.7 
cd8 c2,1 L 37.9 0.595 1.18 1.86 0.93 0.59 0.150 149.079 0.038 3,964.6 
cd8 c3,2L 33.9 0.451 1.66 2.19 1.10 0.83 0.492 57.272 0.040 1,426.8 
cd8 C3,1 L 38.4 0.484 1.02 1.2 0.60 0.51 0.063 313.162 0.026 11,843.0 
cd8c3,10 
L 
32.8 0.473 1.26 1.52 0.76 0.63 0.217 95.137 0.032 2,981.4 
Average 36.3 0.508 1.35 1.67 0.83 0.68 0.243 137.487 0.037 4.2050 
Adjusted 
Ave 
36.3 0.508 1.35 1.67 0.83 0.68 0.243 137.487 0.037 4.205.0 


















Stress Strain Young's 
modulus 
UoM (N) (mm) (mm) (mm) (mm) (mm) (mmSq) (N /mmSq) 
Calc'd A B C 0 E =D /2 F =C /2 G =E x 
Fcubed x 
Pi /4 
H =A x 2F/ 
2G 
I=6F x B/ 
56 





49 0743 338 526 263 169 9970 0 838 0 134 62 
cd8 c1.30 
R' 
32.2 0.434 3.9 6.17 3.09 1.95 17.966 3.494 0.091 38.5 
cd8 
c2,1 R' 
18.8 1.310 3.32 3.69 1.85 1.66 6.628 4.702 0.233 20.2 
cd8 
c3,2R' 
15.9 1.209 4.44 6.14 3.07 2.22 26.381 1.334 0.288 4.6 
cd8 
c3,111' 
32.0 1.024 3.65 5.9 2.95 1.83 14.083 4.142 0.200 20.7 
cd8 C3,10 
R' 
15.1 1.373 4.22 5.37 2.69 2.11 19.810 1.612 0.310 5.2 
Average 19.8 1.015 3.82 5.42 2.71 1.91 15.806 2.687 0.209 15.9 
Adjusted 
Ave 
22.8 1.070 3.91 5.45 2.73 1.95 16.974 3.057 0.224 17.8 
Table XVII: 4 Point bending results for Depleted CD8' T Fractured Right tibia. Data in blue excluded in adjusted average. 
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